Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Understanding Non-Hodgkin Lymphoma A Guide For Patients, Survivors, and Loved Ones Fourth Edition This guide is an educational resource compiled by the Lymphoma Research Foundation (LRF) that provides general information on adult non-Hodgkin lymphoma. Publication of this information is not intended to take the place of medical care or the advice of a patient’s doctor. Patients are strongly encouraged to talk to their doctors for complete information on how their disease should be diagnosed, treated, and followed. Before starting treatment, patients should discuss the potential benefits and side effects of cancer therapy. National Headquarters 115 Broadway, Suite 1301 New York, NY 10006 (212) 349-2910 phone (212) 349-2886 fax Helpline: (800) 500-9976; [email protected] Website: www.lymphoma.org Email: [email protected] This patient guide is supported through unrestricted educational grants from: ™ Turning Insights into Hope © 2012 Lymphoma Research Foundation. Information contained herein is the property of the Lymphoma Research Foundation (LRF). Any portion may be reprinted or reproduced provided that LRF is acknowledged to be the source. ACKNOWLEDGMENTS The Lymphoma Research Foundation wishes to acknowledge those individuals listed below who have given generously of their time and expertise. We thank them for their contributions, editorial wisdom, and advice, which have truly enhanced this publication. The review committee guided the content and development of this publication. Without their dedication and efforts, this publication would not have been possible. We hope those in the lymphoma community will now be better informed and have a better understanding of their illness because of the gracious efforts of those involved in the planning and execution of this comprehensive disease guide. Review Committee Bruce D. Cheson, MD, Georgetown University Hospital, Lombardi Comprehensive Cancer Center Morton Coleman, MD, Weill Cornell Medical College-NewYork Presbyterian Hospital Christopher R. Flowers, MD, Emory University School of Medicine Randy Gascoyne, MD, FRCPC, British Columbia Cancer Agency Stephanie A. Gregory, MD, Rush University Medical Center/ Rush University John P. Leonard, MD, Weill Cornell Medical College–NewYork Presbyterian Hospital Oliver W. Press, MD, PhD, Fred Hutchinson Cancer Research Center, University of Washington Sonali Smith, MD, The University of Chicago Steven P. Treon, MD, PhD, Harvard Medical School Julie M. Vose, MD, MBA, University of Nebraska Medical Center Michael E. Williams, MD, University of Virginia School of Medicine ii Understanding Non-Hodgkin Lymphoma TA B L E O F C O N T E N T S Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Part 1 — Learning the Basics. . . . . . . . . . . . . . . . . . . . . . . . . 2 Chapter 1: Understanding Non-Hodgkin Lymphoma. . . . . . . . 2 Chapter 2: Seeking Medical Help . . . . . . . . . . . . . . . . . . . . . . . 17 Chapter 3: Getting a Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . 20 Chapter 4: Work-up Before Treatment Can Begin . . . . . . . . . 28 Part 2 — Treatment of Non-Hodgkin Lymphoma . . . . . 36 Chapter 5: What You Should Know Before Starting Treatment . . . . . . . . . . . . . . . . . . . 36 Chapter 6: Treatments for Non-Hodgkin Lymphoma . . . . . . . 47 Part 3 — Side Effects and Living With Cancer . . . . . . . 69 Chapter 7: Common Treatment Side Effects . . . . . . . . . . . . . 69 Chapter 8: Managing Your Life During and After Treatment . . . . . . . . . . . . . . . . . . . . . . . . 86 Part 4 — Clinical Trials and Advances in Treatment . . 91 Chapter 9: Overview of Clinical Trials . . . . . . . . . . . . . . . . . . . 91 Chapter 10: Advances in Treatment of Patients With Non-Hodgkin Lymphoma . . . . . . . . . . . . . . 96 About the Lymphoma Research Foundation . . . . . . . . . . . . . . . . . . . 99 Understanding Non-Hodgkin Lymphoma iii INTRODUCTION The purpose of this booklet is to help patients with non-Hodgkin lymphoma become active participants in their healthcare decisions. Chapters in this book address different issues faced by these patients, including: what to expect during diagnosis, work-up, and treatment; how to cope with treatment side effects; and what questions to ask doctors. 1 Understanding Non-Hodgkin Lymphoma Part 1 — Learning the Basics Chapter 1: Understanding Non-Hodgkin Lymphoma Part 1 Non-Hodgkin lymphoma (NHL) is a type of blood cancer that affects specialized white blood cells called lymphocytes. Lymphocytes work together with other cells in the immune system to defend the body against invasion by bacteria, viruses, parasites, and other foreign substances. Lymphocytes travel in the bloodstream and in a separate network of vessels called the lymphatic system. The sections in this chapter will explain these and other terms that will help you understand NHL and how it affects a person’s health. A better understanding of the disease will help patients take a more active role in deciding the course of their treatment. What is cancer? Cancer is a group of diseases that develop when abnormal cells gain the ability to divide abnormally and to spread to areas in the body where they are not normally found. Your body is made up of many different types of specialized cells that are organized into tissues and organs to perform all the different tasks needed to stay healthy. To keep things running smoothly, the cells in your body grow, work, and divide in a very controlled fashion. All of these cells also have a limited lifespan. Normally, a self-destruct mechanism is triggered when a cell becomes too old or when it stops working properly. However, sometimes damage to the genetic material (DNA) of a cell gives it the ability to override this self-destruct mechanism, allowing these abnormal cells to live longer or divide more frequently than normal. Unless the body’s immune system gets rid of them, these abnormal cells can multiply and cause cancer. Learning the Basics 2 HOW CANCER FORMS INSIDE THE BODY Abnormal Cells Evade the Immune System Abnormal Cells Multiply (Cancer) Tumors May Form (Groups of Abnormal Cells) Most cancers are named after the organ or cell type of origin. For example, a cancer that started in the pancreas is called pancreatic cancer and a cancer that started in lymphocytes is called a lymphoma. 3 Understanding Non-Hodgkin Lymphoma Why is there no single cure for cancer? There are also smaller, but still important, differences in the cancer cells found in different patients diagnosed with the same type of cancer. Because of this, a treatment that may work very well in one patient may not have the same positive effect in another. These are some of the reasons why most cancers are much harder to treat or prevent than, for example, bacterial or fungal infections, which typically are caused by a single type of organism. What is the lymphatic system? As shown in the picture on page 5, the lymphatic system is a circulatory system that is made up of a spidery network of thin tubes called lymph vessels. Similar to blood vessels, lymph vessels branch out into all tissues of the body. While people can clearly see blood vessels, especially at their wrists and on the top of their hand, lymph vessels are invisible to the naked eye. Learning the Basics 4 Part 1 Cancer refers to a large group of very complicated diseases. A tricky aspect of cancer is that there are many different ways for a cell to become abnormal enough to develop into a cancer cell. Because of this, the path taken by a liver cell to become a cancerous liver cell is quite different from that taken by a lymphocyte to become NHL. This is why a treatment that works against one type of cancer may not necessarily work against another. There are also important differences between different kinds of NHL, and a treatment that works against one type of NHL may not necessarily be the best treatment choice for another type. ANATOMY OF THE IMMUNE SYSTEM The immune system is the body’s defense against disease. Tonsil Thymus Diaphragm Lymph nodes Spleen Lymph vessels 5 Understanding Non-Hodgkin Lymphoma Lymph fluid flows through lymph nodes and specialized lymph tissues such as the spleen, tonsils, bone marrow, and thymus gland. Lymph nodes filter lymph fluid, removing bacteria, viruses, and other foreign substances from the body. If a large number of foreign substances are filtered through a node or series of nodes, swelling may occur and the nodes may become tender to the touch. Most swollen nodes are a reaction to infection and are not cancerous. What is a lymphoma? A lymphoma is a cancer that affects lymphocytes, a type of white blood cell. Lymphocytes travel through the blood and lymphatic system to defend the body against foreign invaders like bacteria and viruses. There are 2 major categories of lymphomas: non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). NHL is approximately 8 times more common than HL; according to the American Cancer Society, each year in the United States over 70,000 adults are diagnosed with NHL and approximately 9,000 with HL. Both of these major categories of lymphoma are further subdivided into several types that are different in the way they develop and spread, and in how affected patients are treated. Lymphomas usually develop when a change, or mutation, occurs within a lymphocyte, causing the abnormal cell to replicate faster than, or live longer than, a normal lymphocyte. Like normal lymphocytes, cancerous lymphocytes can travel through the blood and lymphatic system and spread and grow in many parts of the body, including the lymph nodes, spleen, bone marrow, and other organs. This is why most types of NHL are found throughout the body by the time a patient is diagnosed with the disease. Learning the Basics 6 Part 1 Lymph vessels carry lymph, a type of liquid that contains lymphocytes. Within this huge network of vessels are groups of small, bean-shaped organs called lymph nodes. Thousands of lymph nodes are found throughout the body, including the elbows, neck, armpits, chest, abdomen, and groin. What is non-Hodgkin lymphoma? NHL does not refer to a single disease, but to a large group of related cancers that occur in lymphocytes. NHL is the seventh most common type of cancer affecting adults of both sexes. The World Health Organization estimates that there are approximately 60 types of NHL. While these various types share many common features, certain characteristics set them apart from each other, including: n How they look when examined under a microscope. n Genetic characteristics and other molecular features. n How and where they grow in the body. n How their growth and spread affect patients. n How patients should be treated. How are non-Hodgkin lymphoma types organized? NHL is divided into the following 2 major groups: n n 7 B-cell lymphomas — These lymphomas develop from abnormal B-lymphocytes (“B” because B-lymphocytes come from the bone marrow) and account for 85% of all NHL. T/NK-cell lymphomas — These lymphomas develop from abnormal T-lymphocytes (“T” because normally T-lymphocytes spend part of their lifespan in the thymus gland, a small organ in the chest) or natural killer (NK) cells. These account for the remaining 15% of NHL. Understanding Non-Hodgkin Lymphoma RELATIVE FREQUENCIES OF B-CELL LYMPHOMAS Follicular 29% Diffuse large B-cell 37% MALT 9% Part 1 Mantle cell 7% Chronic lymphocytic/ small lymphocytic 12% Primary mediastinal large B-cell 3% High Grade B, not otherwise specified 2.5% Lymphoplasmacytic 1.4% Burkitt 0.8% Nodal marginal zone 2% Splenic marginal zone 0.9% RELATIVE FREQUENCIES OF T-CELL LYMPHOMAS Peripheral T-cell, not otherwise specified 25.9% Angioimmunoblastic 18.5% Extranodal natural killer/T-cell 10.4% Adult T-cell leukemia/ lymphoma 9.6% Anaplastic large cell, ALK+ 6.6% Anaplastic large cell, ALK- 6.6% Other disorders 12.2% Unclassifiable peripheral T-cell 2.5% Enteropathy-type T-cell 4.7% Primary cutaneous anaplastic large cell 1.7% Subcutaneous panniculitis-like 0.9% Hepatosplenic T-cell 1.4% Learning the Basics 8 NHL types are also often grouped according to how quickly they grow: n n Indolent lymphomas (also called low-grade lymphomas) grow slowly and tend to cause few symptoms. While indolent lymphomas are usually not curable, patients can live a long time with these types of lymphomas because they respond well to treatment and may potentially remain in remission for many years (even decades). Over time, some indolent lymphomas may transform into aggressive lymphomas. Aggressive lymphomas (also called intermediate-grade and highgrade lymphomas) grow and spread more quickly than indolent lymphomas. Aggressive lymphomas, while potentially lifethreatening, can often be cured with chemotherapy and other newer treatments. This table lists some of the main types of indolent and aggressive NHL. Indolent Non-Hodgkin Lymphomas Aggressive Non-Hodgkin Lymphomas Follicular lymphoma Diffuse large B-cell lymphoma (DLBCL) Chronic lymphocytic leukemia/ small lymphocytic lymphoma Burkitt lymphoma Marginal zone lymphoma Lymphoplasmacytic/Waldenström macroglobulinemia Lymphoblastic lymphoma Mantle cell lymphoma Peripheral T-cell lymphoma, unspecified Anaplastic large-cell lymphoma Mycosis fungoides/Sézary syndrome (subtypes of cutaneous T-cell lymphoma) Angioimmunoblastic lymphoma Blastic natural killer (NK)-cell lymphoma Pathologists (doctors who specialize in disease diagnosis) can distinguish among the many different types of NHL by examining biopsy tissue samples under a microscope and by carrying out various laboratory tests. This information is critically important in deciding how to treat the affected patient. 9 Understanding Non-Hodgkin Lymphoma Common types of aggressive non-Hodgkin B-cell lymphoma Diffuse large B-cell lymphoma DLBCL can arise in the lymph nodes or outside the lymphatic system. It may be localized or generalized (spread throughout the body). Despite being an aggressive lymphoma, DLBCL is curable. The first sign of DLBCL is usually rapid swelling in the neck, armpit, or groin caused by enlarged lymph nodes. Other symptoms include night sweats, chills, unexplained fevers, and weight loss. Mantle cell lymphoma Mantle cell lymphoma affects approximately 6% of all patients with NHL. This type of lymphoma usually affects men over 50 years. Often, patients with mantle cell lymphoma have many lymph nodes, 1 or more organs, and the bone marrow involved. The gastrointestinal tract is a very common extra-nodal site of involvement. Mantle cell lymphoma may sometimes follow an indolent, or slow-growing, course but more typically behaves as an aggressive disease and is, therefore, often treated as an aggressive lymphoma. For more information on mantle cell lymphoma, please visit LRF’s “Focus on Mantle Cell Lymphoma” website at www.focusonmcl.org. Common types of indolent non-Hodgkin B-cell and T-cell lymphoma Follicular lymphoma Follicular lymphoma (FL) is the second most common type of NHL. FL accounts for about 22% of all NHLs. FL typically occurs in middleaged and older adults, but it can also affect younger adults. FL usually appears in lymph nodes spread throughout the body. Often, one of the first signs of FL is a painless swelling in the neck, armpit, or groin caused by these enlarged lymph nodes. FL may eventually transform Learning the Basics 10 Part 1 Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL, accounting for up to one-third of newly diagnosed NHL patients. The median age at diagnosis is 57 years, but the disease is also seen in younger people. into a more aggressive form of the disease. For more information on FL, please visit LRF’s “Focus on Follicular Lymphoma” website at www.focusonfl.org. Chronic lymphocytic leukemia/small lymphocytic lymphoma Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies involving lymphocytes. The main difference between the 2 diseases is where the cancer primarily occurs. If the cancer cells are found mainly in lymph nodes, the disease is called SLL. If the cancer cells are found in the bloodstream and bone marrow, the disease is called CLL, although the lymph nodes and spleen are often also involved. Approximately 16,000 new cases of CLL and 5,000 new cases of SLL are diagnosed annually. CLL/SLL are usually diagnosed in adults over age 50; more than half of the people with CLL are over age 70. Thinking of CLL/SLL as a lymphoma and not a form of leukemia is important because CLL has a clinical course and treatment regimen that is similar to other indolent lymphomas. Over time, CLL may progress to a more aggressive type of lymphoma (Richter’s syndrome). The staging system for CLL is different from the staging system applied to other NHLs. For a more detailed description of CLL, visit www.focusoncll.org or request a copy of the Lymphoma Research Foundation’s publication entitled Understanding CLL/SLL: A Guide for Patients, Survivors and Loved Ones. Marginal zone lymphoma Marginal zone B-cell lymphomas account for approximately 7% of all NHLs. The median age of diagnosis of this type of lymphoma is 65. These lymphomas include 3 basic types: (1) extranodal or mucosaassociated lymphoid tissue (MALT), occurring outside the lymph nodes; (2) nodal, occurring within the lymph nodes; and (3) splenic, occurring mostly in the spleen and blood. Skin-associated lymphoid- 11 Understanding Non-Hodgkin Lymphoma tissue-related B-cell lymphoma (SALT) is also considered a form of MALT lymphoma. n n n n n Part 1 Marginal zone and MALT lymphomas vary from other types of B-cell NHLs in several ways: Many people who develop MALT lymphoma have a history of inflammation, infection, or autoimmune disorders. Chronic inflammation is associated with Helicobacter pylori (H. pylori), a microbial pathogen linked to chronic gastritis. Sometimes, MALT lymphomas can be treated with antibiotics. Different infections have also been implicated in other forms of MALT lymphoma. Hepatitis C virus infection has been associated with splenic marginal zone lymphoma. Waldenström macroglobulinemia Waldenström macroglobulinemia (also known as lymphoplasmacytic lymphoma or immunocytoma) is a rare B-cell lymphoma that occurs in less than 2% of people with NHL. There are about 1,500 new cases of Waldenström’s each year. The disease usually affects older adults and is primarily found in the bone marrow, although lymph nodes and spleen may sometimes be involved. People with Waldenström’s have a high level of a protein called immunoglobulin M (IgM) in the blood. These high levels of IgM can cause a thickening of the blood, resulting in symptoms such as nosebleeds, headaches, dizziness, and blurring or loss of vision. Cutaneous T-cell lymphoma Cutaneous T-cell lymphomas (CTCL), a group of lymphomas that originate in the skin, are a subset of peripheral T-cell lymphoma (PTCL). However, CTCL types are generally less aggressive, have a different prognosis, and have different treatment approaches than the aggressive PTCLs. Mycosis fungoides is the most common type of CTCL. Sézary syndrome is an advanced, variant form of mycosis fungoides, and affects both the skin and the peripheral blood. Learning the Basics 12 Common types of aggressive non-Hodgkin T-cell/natural killer cell lymphoma Peripheral T-cell lymphomas PTCL refers to a large number of different T-cell lymphomas that together affect 5-10% of all patients diagnosed with NHL. This type of lymphoma can occur anytime during adulthood. Some varieties of PTCL are rare in the United States but can more commonly be found in Asia, notably Japan, where an infection with a virus called HTLV-1 is prevalent. Its presence makes it more likely for an individual to develop a specific type of PTCL. It has also been found in individuals coming from Caribbean countries. For more information on PTCL, please visit LRF’s “Focus on Peripheral T-Cell Lymphoma” website at www.focusonptcl.org. Anaplastic large-cell lymphoma Anaplastic large-cell lymphoma (ALCL) is rare, affecting about 3% of adults with all types of lymphomas and 10-30% of children with all types of lymphomas. ALCL occurs either systemically (meaning in organs in the body) or cutaneously (meaning on the skin surface). Systemic ALCL can respond well to chemotherapy and is potentially curable. The cutaneous (skin) ALCL is a less aggressive disease that is associated with a rare condition called lymphomatoid papulosis (LyP), which is often a precursor to the development of cutaneous anaplastic large-cell lymphoma. Patients with systemic ALCL are divided into 2 groups, depending on the expression of a protein called anaplastic lymphoma kinase (ALK). The prognosis for ALCL depends on whether a patient is ALK positive (expresses the protein) or ALK negative (does not express the protein). ALK positive disease responds well to chemotherapy, putting most patients in long-term remission or cure. A majority of ALK negative patients will relapse within 5 years and are treated more aggressively, often with transplant. For more information on ALCL, please visit LRF’s “Focus on Anaplastic Large Cell Lymphoma” website at www.focusonalcl.org. 13 Understanding Non-Hodgkin Lymphoma Angioimmunoblastic lymphoma Initially, AITL may be treated with steroids. However, the disease often progresses and patients require chemotherapy and other medications. In advanced cases, transplantation may be used. Lymphoblastic lymphoma Lymphoblastic lymphoma can appear in both B cells and T cells but is much more common in T cells (which are affected in 80% of all lymphoblastic lymphomas). This lymphoma is most often diagnosed in children. With intensive chemotherapy, the complete remission rate can be very high. The disease is often treated similarly to acute lymphoblastic leukemia. Blastic natural killer-cell lymphoma Blastic natural killer (NK)-cell lymphoma is a very rare form of lymphoma that affects the NK cells of the immune system. NK cells are a type of lymphocyte that attack and destroy viruses and tumor cells. This type of lymphoma usually affects older adults. Patients with blastic NK-cell lymphoma have skin lesions that are similar to those associated with leukemia, other cutaneous lymphomas, and other skin diseases. It can only be diagnosed by specific laboratory tests. This disease is hard to treat. The best results have been obtained using a combination of chemotherapy and radiation therapy, followed by bone marrow transplantation. Learning the Basics 14 Part 1 Angioimmunoblastic lymphoma (AITL) affects 1-2% of all patients with NHL in the United States. Symptoms include high fever, night sweats, skin rash, and some types of autoimmune disorders, such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP), in which the body does not recognize its own cells. Because of this, the body makes antibodies against and destroys its own cells or tissues, such as platelets (ITP) and red blood cells (AIHA). Why do some people develop non-Hodgkin lymphoma? The reasons why some people develop NHL are not well understood. However, scientists have found that people with certain characteristics have a higher risk of developing NHL compared with people who do not have these characteristics. The characteristics that make a person possibly more susceptible to developing any type of disease are called risk factors. Having 1 or more of these risk factors does not mean a person will develop NHL. In fact, most people with risk factors never develop the disease and many people diagnosed with NHL have never been exposed to any clearly identifiable risk factors. Known risk factors for NHL include: n n n n n n 15 A weakened immune system caused by an inherited immune disorder (for example, hypogammaglobulinemia, Wiskott-Aldrich syndrome), an autoimmune disease (for example, Crohn’s disease, rheumatoid arthritis, psoriasis), or treatment with certain drugs used after an organ transplant. Infections with certain viruses, such as human immunodeficiency virus (HIV which is the virus that causes AIDS), Epstein-Barr virus (EBV), human T-cell leukemia/lymphoma virus (HTLV-1), hepatitis C virus. Infection with the bacteria Helicobacter pylori (which may cause stomach ulcers and may increase the risk of developing lymphoma in the stomach lining). Older age—NHL may develop in children and adults of all ages but, like most cancers, it is much more common in people older than 60 years of age. Sex—NHL is more common in men compared with women. Being exposed to certain chemicals such as benzene, certain herbicides and pesticides, and some chemotherapy drugs used to treat other cancers or autoimmune disease. Understanding Non-Hodgkin Lymphoma n n Treatment with radiation therapy for some other cancers, including NHL. Previous treatment for NHL. Learning the Basics 16 Part 1 NHL cannot be caused by injury or by catching it from someone who has the disease. The children and siblings of patients with NHL have a slightly increased risk of developing this disease compared to the general population. However, there are no clearly identified genetic or hereditary factors to predict this slightly increased risk, and routine screening for NHL is not recommended. Part 1 — Learning the Basics Chapter 2: Seeking Medical Help This chapter explains the signs and symptoms of NHL and discusses how a doctor determines whether or not a person has the disease. A symptom is anything unusual in a normal body function, appearance, or sensation that a patient experiences. During a visit with a healthcare practitioner, patients should report all of their symptoms to their doctor or nurse. Symptoms may indicate the presence of lymphoma or another disease. Signs are anything unusual that doctors or nurses notice when they examine their patients. What are the signs and symptoms of non-Hodgkin lymphoma? Some patients with NHL do not experience any symptoms. Their disease may be detected initially by their doctor during a routine physical examination or only after the tumor becomes large enough to cause symptoms. General symptoms of NHL can include: n Unexplained weight loss. n Fever for no known reason. n Drenching night sweats that soak clothing and sheets. n Severe or frequent infections. n Easy bruising or bleeding. n Numbness or tingling in feet and/or hands. n Headaches and/or blurry vision. n Fatigue. 17 Understanding Non-Hodgkin Lymphoma Having one or more of these symptoms does not mean that a person has NHL. These symptoms may be caused by an infection or other conditions (including other cancers). Signs and Symptoms Possible Reason Lumps under the skin on the sides of the neck, in the groin or underarms, or above the collar bone This may be caused by swollen lymph nodes which is a common symptom of lymphoma Swollen, tender abdomen (belly) Enlarged lymph nodes in the abdomen Accumulation of large amounts of liquid in the abdomen Enlarged spleen pressing on the stomach (making a person feel full after eating only a small amount of food) Abdominal pain, nausea, or vomiting Lymphoma in the intestine or causing swelling near the intestine, possibly blocking bowel movements Stomach pain, nausea, and decreased appetite Lymphoma of the stomach Coughing, trouble breathing, chest pain, or pressure Lymphoma in the chest which may press on the windpipe (trachea) Headache, trouble thinking, weakness in certain parts of the body, personality changes, and sometimes seizures Lymphoma of the brain Double vision, facial numbness, trouble speaking Lymphoma originating in other parts of the body before spreading to the brain and spinal cord Itchy, red, or purple lumps or nodules under the skin Lymphoma of the skin Learning the Basics 18 Part 1 NHL may cause different signs and symptoms depending on the location of the tumor in the body. This table gives some examples of signs and symptoms that may indicate the presence of a lymphoma in a specific part of the body. Be aware that none of these signs and symptoms are specific to NHL exclusively, and may be due to a variety of other conditions. When should a patient seek medical attention? Anyone who has persistent symptoms should see a doctor to make sure that lymphoma or another serious condition is not present. A good rule of thumb is to seek medical attention if any of the previously mentioned symptoms last longer than 2 weeks or sooner depending on their severity and impact on a person’s daily life. Many of these symptoms can arise from different causes and need not be cancer. There are no specific tests that doctors can use to routinely screen patients to see if they have NHL. During the visit with the doctor, patients should describe all of their symptoms. The doctor will ask detailed questions about medical history and perform a complete physical examination. During the physical examination, the doctor will: n n n n n Check for swollen lymph nodes under the chin, in the neck and tonsil area, above the shoulders, on the elbows, in the armpits, and in the groin and upper legs. Examine other parts of the body to see if there is swelling or fluid in the chest or abdomen that may be caused by swollen lymph nodes. Examine the abdomen to see whether any internal organs are enlarged. Ask about any pain experienced. Look for any weakness or paralysis that may be caused by an enlarged lymph node pressing against nerves or the spinal cord. If doctors suspect lymphoma after reviewing the symptoms reported and signs they have uncovered during the examination, they will order other tests to confirm the diagnosis. These tests should include a biopsy and may also include blood tests, chest x-rays and other imaging tests, scans, and a bone marrow evaluation. Depending on the type and location of the NHL, other tests may be required. These tests and procedures are discussed in more detail in the next chapter. 19 Understanding Non-Hodgkin Lymphoma Part 1 — Learning the Basics Chapter 3: Getting a Diagnosis Cautions About Interpreting Diagnostic Reports n n n n n n n Only a biopsy is definitive. Tests can be reported as “normal” even though lymphoma may be present. Tests may be reported as “abnormal” even though lymphoma is not present. Other conditions may mimic NHL. The interpretation of tests, such as imaging studies and scans, can be difficult in some situations and needs to be made in the context of the disease and the patient. Often, follow-up tests are needed to determine the true significance of previous results; additional biopsies may be needed to clarify the results. Some patients like to review their written scan reports; when doing so, it is important to carefully review the findings with their doctor. Learning the Basics 20 Part 1 Doctors need the results of different diagnostic tests to accurately determine whether or not a patient has NHL. This chapter explains the purpose of these different tests and describes what to expect during and after these procedures. How is non-Hodgkin lymphoma diagnosed? The only way to be absolutely sure of a diagnosis of NHL (or any cancer) is for a doctor to perform an excisional biopsy to remove an entire lymph node or an incisional biopsy to remove a portion of the diseased tissue (see below, “What is a biopsy?”). A pathologist will examine a portion of this biopsy sample under a microscope to see if it contains any lymphoma cells and, if possible, to identify the specific type of lymphoma. A surgical pathologist is a doctor who specializes in the diagnosis of diseases by studying the cells from a patient’s blood, body fluids, and tissue samples. A hematopathologist specializes in the pathology of blood cells, and a lymphoma pathologist specializes in the diagnosis and classification of NHLs and HLs. These doctors are trained to recognize different cell types by looking at the shape and size of cells and how they are grouped inside a tissue. In addition to routine pathology analyses, portions of biopsy samples will be used for other tests to confirm the diagnosis and to more exactly identify the specific subtype of lymphoma. This chapter explains how these tests work and what kind of information they provide. What is a biopsy? A biopsy is a procedure in which a piece of tissue from an area of suspected disease is removed from the body and examined under a microscope. The information provided by this tissue sample is crucial to correctly diagnose the disease and decide on the best course of treatment. 21 Understanding Non-Hodgkin Lymphoma The following are the 2 main types of biopsies doctors use for the initial diagnosis of patients with a lymphoma: n n n Core Needle Biopsy n n n n This type of biopsy is the best to establish an initial diagnosis of lymphoma because it allows for the removal of bigger samples than other biopsy procedures. The larger the sample, the more tissue the pathologist can examine, which improves the accuracy of diagnosis. Part 1 Excisional or Incisional Biopsy In this procedure, a surgeon cuts through the skin to remove an entire lymph node (excisional biopsy) or a large portion of tissue (incisional biopsy). If the lymph node is close to the skin surface, the procedure can be done under local anesthesia to numb the area. If the lymph node is in the chest or abdomen, the patient is sedated and the surgeon removes the tissue either laparoscopically (through a tube inserted in the abdomen) or by performing abdominal surgery. This procedure is used when the lymph nodes are deep in the chest or abdomen or in other locations that are difficult to reach with excisional biopsy, or when there are medical reasons for avoiding an excisional or incisional biopsy. In this procedure, a large needle is inserted into a lymph node suspected to be cancerous and a small tissue sample is withdrawn. A needle biopsy can be done under local anesthesia and stitches are usually not required. Sometimes the material collected may not be adequate for diagnosis and a subsequent excisional or incisional biopsy may be necessary. A fine needle aspirate (FNA) biopsy is, as the name implies, a type of biopsy performed with a very thin needle (smaller than that used for a core needle biopsy). Because of the small needle size, the sample will only contain scattered cells without preserving how the cells are actually arranged in the lymph node. This limited information is not enough for a precise diagnosis. An FNA biopsy is most often used to check for return of the disease (relapse) and is virtually never used for the initial diagnosis. Learning the Basics 22 After a biopsy sample has been removed, it is examined by a pathologist who develops a report. An oncologist then uses this report along with results of other diagnostic tests to confirm a diagnosis. A pathologic diagnosis and accurate classification of specific lymphoma types can sometimes be difficult to make; if the pathologist’s interpretation of the biopsy is uncertain, the results should be reviewed by a hematopathologist or a lymphoma pathologist. Second opinions can be helpful, because an accurate diagnosis is crucial in planning the most appropriate treatment plan. What are a bone marrow biopsy and a bone marrow aspiration? Bone marrow is a wet, spongy tissue inside bones where blood cells are generated. A bone marrow biopsy involves removing a small amount of bone marrow from inside a bone. The bone marrow is then examined for the presence of lymphoma cells. A bone marrow aspiration is similar to a bone marrow biopsy except it involves removing only the liquid portion of the marrow, using a fine needle inserted into a bone. A bone marrow biopsy or aspiration is not used for initial diagnosis but is commonly used to see if the NHL has spread, or to collect bone marrow for medical procedures such as stem cell transplant or chromosomal analysis (see page 34, “Why might a patient need to have another type of biopsy?”). What questions should a patient ask the doctor before having a biopsy or other diagnostic procedure? Patients diagnosed with a complicated disease will be asked to undergo a variety of procedures for the initial diagnosis and work-up before treatment begins, during the course of treatment, and during the follow-up period. Before patients agree to a procedure, they should make sure that they understand the reasons for the procedure and what will be involved. Here is a list of questions patients may want to ask their doctor. n Why is this procedure necessary? n What will the procedure tell us about my condition? 23 Understanding Non-Hodgkin Lymphoma Can the same information be obtained in another way? n What is involved in doing this procedure? n What are the possible risks, complications, and side effects? n Where will I have the procedure done? n Will I have to do anything to prepare for the procedure? n How long will the procedure take? Will I be awake? Will I feel pain? n How long will it take for me to recover from the procedure? n Should anyone else be present when I have the procedure? n Will I need someone to take me home afterward? n When will I know the results? n When will we talk about the results? n What will be my out-of-pocket costs? Part 1 n What is immunophenotyping? Immunophenotyping is a process used during evaluation of biopsy material to distinguish between different types of cells (for example, between normal lymphocytes and lymphoma cells), by detecting specific molecules (cell “markers” or “antigens”) found on the cell surface. These cell markers are detected using special antibodies grown and chemically modified in the laboratory so that they will change color when they stick to their corresponding markers. Learning the Basics 24 IMMUNOPHENOTYPING Antibodies change color upon binding to specific cell markers. Antibody Antigen This color change is studied under a microscope using immunohistochemistry (IHC) analysis or sorted and counted using a process called flow cytometry. Sometimes, both IHC and flow cytometry are necessary for accurate immunophenotyping. 25 Understanding Non-Hodgkin Lymphoma Immunohistochemistry (IHC) n n Flow Cytometry n n n Part 1 n In this test, thin slices of the biopsy sample (or thin layers of fluid or blood) are placed on slides and treated with sets of antibodies that recognize different markers found in different types of lymphoma cells and normal lymphocytes. The pathologist examines the slides under a microscope to look for the visible color change that happens when the antibody sticks to the marker. The pathologist identifies and counts the number of cells that change color (meaning that they are positive for the marker) with each of the different antibodies and uses that information to identify the specific type of lymphoma. In this test, cells from the biopsy sample are placed in a liquid solution and treated with sets of antibodies that recognize different markers found in different types of lymphoma cells. The cell-antibody mixture is injected into an instrument called a flow cytometer. This machine uses laser beams to sense the different colors the cells emit because of the different antibodies attached to them. This information is measured and analyzed by a computer. The results from the flow cytometry analysis will distinguish between different types of lymphoma, other cancers, or some other disease. Learning the Basics 26 What is cytogenetic analysis? Chromosomes are long strands of DNA, the genetic material of a cell. Healthy human cells have 23 pairs of chromosomes. Some lymphomas and other types of cancer have too few or too many chromosomes, or have abnormal chromosome structures. In cytogenetic analysis, chromosomes from a patient’s lymphoma cells are examined under a microscope to check for changes in their number (too few or too many) or the presence of other abnormalities. One type of chromosomal abnormality that can be seen through a microscope is called a translocation—which happens when part of a chromosome breaks off from its normal location and becomes attached to another chromosome. The results of the cytogenetic analysis can help distinguish between different types of NHL. CHROMOSOME TRANSLOCATION Two different chromosomes exchange portions of their genetic material. Chromosome 14 Chromosome 18 Bcl2 Bcl2 Translocation It usually takes 1 to 2 weeks to get the results from cytogenetic testing because a sufficient number of patient’s lymphoma cells must be grown in the laboratory to get enough genetic material for the analysis. 27 Understanding Non-Hodgkin Lymphoma Part 1 — Learning the Basics Chapter 4: Work-up Before Treatment Can Begin Part 1 After the initial diagnosis of NHL, the doctor may order other tests such as blood tests, molecular genetics tests, imaging studies, heart and lung function tests, and, less frequently, additional biopsies. This process is often called the work-up. Some of these work-up studies are needed to see if and how much the disease has spread to other parts of the body. Doctors will use these test results to determine the stage of a patient’s disease. Other tests will check how the disease has affected a patient’s overall health and major organ functions. Together all of these tests will provide the information needed to help patients and their doctors decide on the course of treatment that will give patients the best chance for curing the disease or putting it into a lasting remission. This chapter will help you understand how NHL is staged, the reason for the various tests, how these tests work, and what to expect. How is non-Hodgkin lymphoma staged? Staging is used to describe how widely the lymphoma has spread in adult patients with NHL. As shown in the following figure, there are 4 main stages of lymphoma, designated by the Roman numerals I through IV. This staging system divides the body in half using the diaphragm, the muscle that divides the chest cavity from the abdominal cavity. Learning the Basics 28 STAGING OF NON-HODGKIN LYMPHOMA Stage I: • Localized disease • Single lymph h node region • Single organ outside lymph ph nodes Stage II: • Two or more lymph node regions near each other • One or more lymph nodes and one organ near each other Stage III: • Two or more lymph node regions in different parts of the body with or withoutt involvement of a nearby organ or the spleen Stage IV: • Widespread W disease dis d • Multiple organs M • With W or without lymph lyym node involvement inv Your doctor may also add any of the following single letters to the stage. n n n A — if patients have not experienced symptoms such as significant weight loss (more than 10% in 6 months), drenching night sweats, or fevers. B — if patients have lost weight (more than 10% in 6 months) and have experienced drenching night sweats or fevers. X — if patients have a lymphoma that is greater than 10 cm (4 inches) wide. This is also called bulky disease. Being diagnosed with stage III or IV NHL is common. Keep in mind that these advanced stages can be successfully treated. 29 Understanding Non-Hodgkin Lymphoma What is the purpose of blood tests? Part 1 Doctors will test a patient’s blood to measure the quantity of the different types of cells (red blood cells, white blood cells, and platelets). This information can help determine how advanced the lymphoma is. These blood tests will most likely include: a complete blood count (CBC), differential (to measure the relative amounts of different types of white blood cells), platelets, and serum lactate dehydrogenase (LDH). Fast-growing lymphoma can cause very high blood levels of LDH. Doctors will also most likely order a comprehensive metabolic panel to measure the amount of different chemicals in your blood, which will show whether the lymphoma is affecting the main body organs. The comprehensive metabolic panel usually includes 14 specific tests that measure the function of the kidneys and liver, electrolyte balance, acid/base balance, blood sugar, and different blood proteins. Calcium, magnesium, potassium, and sodium are some of the electrolytes found in your body; abnormal levels of electrolytes can make you sick. Depending on the type of lymphoma, the blood may also be tested for signs of infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV). A serum immunoglobulin test (immunoelectrophoresis) may also be performed to test for the presence of certain immunoglobulins (a type of protien) that are sometimes found with certain NHL types. The results from these tests will help patients and their doctors decide between different types of treatments. Many of these blood tests will be repeated during the course of treatment to check how the treatment is affecting the patient’s body functions. What is the purpose of molecular genetic tests? Doctors may order molecular genetic tests to confirm the cytogenetic tests and find out more detailed information about the types of damage to the genetic information of the lymphoma cells in the patient’s body. Learning the Basics 30 The 2 main types of molecular genetic tests used are: Fluorescent In Situ Hybridization (FISH) n n Polymerase Chain Reaction (PCR) n n FISH uses fluorescent chemicals to specifically attach to certain parts of chromosomes to show the presence of translocations and other large abnormalities. FISH can be done on blood or bone marrow samples and the test results are usually available within a few days (quicker than cytogenetic testing). PCR is a test that can detect changes in DNA that are too small to be seen under a microscope, or using cytogenetic analyses or FISH. PCR tests can be done on a very small quantity of lymphoma cells; using this technique, abnormal areas of DNA reproduce in an exponential fashion until they are large enough to be detectable. What types of imaging tests may be used? A patient’s doctor will most likely order imaging tests to help find areas of the body where there may be cancer, to learn how far the cancer has spread, and later on to check how well the treatment is working. Most of these tests are painless and no anesthetic is required. Several types of the following imaging procedures may be needed to thoroughly evaluate the extent of your disease. 31 Understanding Non-Hodgkin Lymphoma X-ray n Computer Tomography (CT) Scan n n n n Magnetic Resonance Imaging (MRI) n n n Findings on a chest x-ray may indicate whether the disease is “bulky.” A CT scan takes x-rays from many different angles around the body. A computer combines the pictures obtained from these different angles to give a detailed image of organs inside the body. Patients with NHL often have CT scans of the neck, chest, abdomen, and pelvis to find out how many lymph nodes are involved, how large they are, and whether internal organs are affected by the disease. The amount of radiation exposure during a CT scan varies depending on the area scanned. Most CT scans confer little risk to the patient, although CT scans of the abdomen and pelvis do add a moderate amount of risk (1 in 500-1,000) to the general lifetime risk of cancer. Before a CT scan, the patient may be asked to drink a contrast liquid and/or get an intravenous injection of a contrast dye that will more clearly outline abnormal areas that may be present in the body. Like a CT scan, an MRI takes images from different angles around the body, but an MRI does not use x-rays like a CT scan; instead it uses magnets and radiofrequency waves. Therefore, an MRI confers no risk of radiation-induced cancer. An MRI can provide important information about tissues and organs, particularly the nervous system, that is not available from other imaging techniques. Because this testing technique works well to get clear images of the bones, brain, and spinal cord, an MRI may be ordered if a doctor wants to see whether the lymphoma has spread in these areas. Learning the Basics 32 Part 1 n X-rays use radiation to take pictures of areas inside the body. The amount of radiation used in most diagnostic tests is so small that it poses little risk to the patient. Positron Emission Tomography (PET) Scan n n n n This test evaluates NHL activity in all parts of the body. To perform the test, radioactive fluorodeoxyglucose (a type of sugar) is first injected into the body. A positron camera is then used to detect the radioactivity and produce cross-sectional images of the body. The amount of radiation used for a PET scan is low and poses little risk to a patient. PET scans help determine how much disease is present (staging) and how well it is responding to treatment. While CT scans show the size of a lymph node, PET scans show if the lymph node is active (still has disease). CT and PET scans are now combined into 1 test (PET/CT). What is a MUGA scan? A MUGA scan (multi-gated acquisition scan) is an imaging test that looks at how well the heart muscle is working. A MUGA scan is done to make sure that the patient’s body can withstand treatment with certain lymphoma drugs that may damage the heart in rare cases. MUGA scans may be done when patients are resting or exercising, depending on what their doctor wants to assess. A doctor will most likely order a MUGA scan if he or she is considering treating a patient with the drug doxorubicin (Adriamycin). This test is needed to make sure that the heart is functioning normally because doxorubicin may be associated with cardiac toxicity. A 2-dimensional echocardiogram (ECHO) is sometimes used instead of the MUGA scan to test heart function. 33 Understanding Non-Hodgkin Lymphoma Why might a patient need to have a lung function test? Why might a patient need to have another type of biopsy? Once the diagnosis of NHL is made, the doctor may order other types of biopsies for additional pathology studies and other tests to see if and how the disease has spread to other parts of the body. With this information, the doctor can properly stage the disease. Bone Marrow Aspiration and Biopsy n n n n n This procedure may be done to determine if the lymphoma has spread to the bone marrow. The bone marrow is the spongy, soft material found inside our bones where normal blood cells are generated. NHL can spread to the bone marrow or start in the bone marrow. For the aspiration part of this procedure, the doctor cleans and numbs the skin over the hip and inserts a thin hollow needle into the bone. The doctor uses a syringe to remove a small amount of liquid from the bone marrow. Even with the numbing local anesthetic, this procedure can be painful for a few seconds while the marrow is withdrawn. For the biopsy part of this procedure (which is usually done right after the aspiration), the doctor inserts a slightly larger needle to take out a small piece of bone and marrow. This procedure may also cause mild pain or a pressure sensation. The procedure does not require any stitches. Patients who are anxious about the test should talk with their doctor and nurse to see whether taking a calming medication before the procedure would be helpful. Learning the Basics 34 Part 1 Lung function tests are done to make sure that the body can withstand treatment with certain lymphoma drugs that may stress a patient’s lung function (e.g., bleomycin, cyclosphophamide). A doctor may order breathing tests before beginning treatment and at other times during treatment to make sure that a patient’s lungs are still working properly. Lumbar Puncture (Spinal Tap) n n n n Pleural or Peritoneal Fluid Sampling n n n 35 Sometimes this procedure is used to determine if the lymphoma has spread to the cerebrospinal fluid (CSF), the liquid found in the brain and spinal cord. Most types of NHL do not spread to the CSF. The doctor will order this test only for patients with certain types of lymphoma or who have symptoms suggesting that the disease has reached the brain. For this procedure, the doctor inserts a thin needle into the lower back after the area has been numbed with a local anesthetic. The doctor then uses a small needle to remove a sample of fluid that will be sent to the lab for analysis. A lumbar puncture can also be used to deliver small amounts of chemotherapy (usually cytarabine or methotrexate) directly into the fluid that bathes the brain. This procedure is used to find out if the lymphoma has spread to the chest or abdomen where it can cause liquid to accumulate. For this procedure, the doctor numbs the skin with a local anesthetic, inserts a small needle, and uses a syringe to remove a sample of the liquid for laboratory analysis. The liquid is called pleural fluid when found inside the chest and peritoneal fluid when found inside the abdomen. Understanding Non-Hodgkin Lymphoma Part 2 — Treatment of Non-Hodgkin Lymphoma Chapter 5: What You Should Know Before Starting Treatment First Steps to Take After Receiving a Diagnosis n n Take care of yourself (eat, sleep, rest, and exercise). Seek the support of family, friends, and others on whom you trust and rely. n Learn about the disease and treatment options. n Find medical care that meets your needs. n Find emotional and social support. n Understand the cost of care and what your insurance will cover. n TIP NT PATIE Maintain a copy of your medical records (paperwork, test results, your own notes). Who will plan and carry out the treatment? The treatment of patients with NHL is usually overseen by a medical oncologist or hematologist who specializes in the treatment of patients with lymphoma and/or blood diseases. Depending on the patient’s healthcare needs, the doctor may refer him or her to work with specialists such as a surgical oncologist and a radiation oncologist. The patient’s healthcare team will also include other healthcare professionals such as an oncology nurse, nurse practitioner, physician assistant, social worker, and registered dietitian. The healthcare team will work together and communicate with you to plan, carry out, and monitor the treatment. Treatment of Non-Hodgkin Lymphoma 36 Part 2 Getting a cancer diagnosis is an overwhelming experience. It is perfectly normal to be shocked by the diagnosis, anxious about the future, and confused about the medical information and decisions that need to be made. This chapter will help you prepare for the start of treatment by explaining the next steps and providing tips for talking with a patient’s doctor about your questions and concerns. What is a prognosis? Prognosis is the medical term doctors use for predicting how the disease will progress and the likelihood for recovery. Prognosis is usually based on information gathered from hundreds or thousands of other patients who have had the same disease. This statistical information provides doctors with a general idea of what to expect when a patient is diagnosed with a specific type of NHL, and also gives guidance on the kinds of treatments that have been most successful in treating that NHL type. Keep in mind that no two patients are alike and that statistics from large groups of people cannot accurately predict what will happen to a specific patient. The doctor most familiar with the patient’s situation is in the best position to help interpret these statistics and understand if and how they may apply to a patient’s particular situation. How will we decide what is the best treatment? There are many effective treatment options for patients with NHL. To identify which treatments may work best, doctors consider the following: n The type of NHL. n The stage and location of the lymphoma. n The presence or absence of lymphoma symptoms. n n How quickly the lymphoma is growing (whether it is an indolent or aggressive lymphoma). Levels of the proteins lactate dehydrogenase (LDH) and beta-2 microglobulin (B2M) in the patient’s blood—higher levels of LDH or B2M suggest that the lymphoma may be in a more advanced stage or an aggressive type. People who have normal levels of these proteins appear to have better outcomes than those with higher levels. n A patient’s overall health and age. n A patient’s preferences. n 37 Whether the treatment is the first the patient has received or if the disease has returned after prior therapy. Understanding Non-Hodgkin Lymphoma A doctor will discuss the risks, benefits, and side effects associated with the different treatment choices applicable to the patient’s particular situation. Share questions and concerns with the doctor so that together you can decide which option is best. Use the following questions to help you make an informed decision. Questions to Ask Before Treatment Begins n n n What is the stage of my disease? Where are the tumors? What are my treatment choices? Which do you recommend for me? Why? Are new treatments being studied? Would a clinical trial be appropriate for me? n Do I need more than one type of treatment? n What is the goal of treatment? n n n n Part 2 n What is my exact diagnosis? May I have a copy of the report from the pathologist? TIP NT PATIE What are the expected benefits of each type of treatment? How will we know if the treatment is working? What tests will I need to have to check if it works? How often will I need to get tested? What are the risks and possible side effects of each treatment? Can these side effects be prevented or controlled? What should I do to take care of myself during treatment? Are there any late or long-term side effects that I should be aware of? n How long will the treatment last? n What are the chances that the treatment will be successful? n How will the treatment affect my normal activities? n How often will I need a checkup? n How much will the treatment cost? Will my insurance cover it? Treatment of Non-Hodgkin Lymphoma 38 When should a patient get a second opinion? Before starting any type of treatment, a patient may consider getting a second opinion—especially if some characteristics of the diagnosis are complicated or uncertain. The purpose of the second opinion is not to question the doctor’s expertise but to make sure that the suggested treatment plan is reasonable and optimal for the patient’s particular case. Do not be concerned that you will offend your doctor by requesting a second opinion. Most doctors will be supportive and helpful if you tell them that you would like to get a second opinion. Ask the doctor if it would be okay to briefly delay the start of treatment to give extra time to get a second opinion. Keep in mind that some insurance programs require second opinions; others may cover it if a patient or doctor requests it. Getting a Second Opinion n n n 39 Some hematologists/oncologists/lymphoma specialists associated with medical schools or cancer centers may provide a consultation and be willing to work together with a local oncologist to provide treatment and follow-up care. As part of the second opinion, another pathologist must review the tissue and blood samples to confirm the diagnosis. Ask your doctor about finding a pathologist with a lot of experience diagnosing patients with lymphoma. To get a second opinion, you will have to provide the consulting doctor a complete copy of all medical records, original x-rays, pathology materials, scans, and reports. When you set up the appointment, ask their office for a list of all the materials they will need. It may be useful to keep your own copy of all these records in case you have questions or concerns later on. Understanding Non-Hodgkin Lymphoma TIP NT PATIE To identify lymphoma specialists to contact for a second opinion: n n n n n Contact the patient referral service at your local hospital and at the nearest hospital associated with a medical school; many hospitals have online directories that can be searched to find a specialist in your area. Visit the American Society of Clinical Oncology (ASCO) at www.cancer.net to search their oncologist database. Part 2 n Ask your current doctors, family members, other patients, friends, and coworkers. Visit the American Society of Hematology (ASH) at www.hematology.org/patients to search for hematologists with an interest in lymphoma. Visit the National Cancer Institute (NCI) at http://cancercenters.cancer.gov/ to identify the nearest NCI-designated cancer center and call or visit their website to find out about their lymphoma specialists. Visit the American Board of Medical Specialists (ABMS) at www.abms.org and click on, “Is My Doctor Board Certified” to find out if doctors are board certified in a particular specialty. How to find an oncologist and treatment center A patient’s primary care doctor will probably have referred them to a specialist—likely a medical oncologist, hematologist, or hematologist/ oncologist. Oncologists are physicians who specialize in diagnosing and treating patients with cancer. Hematologists are physicians who specialize in diagnosing and treating patients with disorders of the blood and lymphatic system. Many physicians are experienced in both areas, and there is some overlap. Before agreeing to treatment by a specific specialist and treatment center, make sure that they will be able to meet all medical and personal needs. Patients should feel comfortable with the healthcare team and the quality of the care they provide. Treatment of Non-Hodgkin Lymphoma 40 Here are some questions to ask to select the best medical team: n n n n n n n n n n n n What are the credentials of the specialist, the other members of the medical team, and the hospital or cancer center? Is the specialist board certified as a medical oncologist and/or hematologist? Has he or she passed qualifying examinations by the American Board of Internal Medicine to certify competency in these specialties? How much experience do the specialist and treatment center have in treating patients with cancer in general, and NHL in particular? How many patients with this disease are being treated here now? Does the specialist and/or center participate in clinical trials? How much time does the specialist spend on research and how much on the treatment of patients with NHL? Is the specialist a member of the American Society of Clinical Oncology and/or the American Society of Hematology? Does the clinic or center have modern surgical facilities and diagnostic equipment? Is the specialist or clinic affiliated with any major medical center or medical school? What arrangements are made for medical coverage after hours and on weekends, in case of an emergency? Is my health insurance accepted at this center? Will the office file claims for reimbursement and process the paperwork? What kind of patient resources does the clinic or cancer center have for patients with my disease? Patients enrolled in a managed care program may have limited choices. However, patients have the right to choose another healthcare team if they are not entirely satisfied with their first consultation visit. They should talk with other patients about their experience and ask them if they would recommend their specialist and healthcare team. Also, patients should share any concerns with their 41 Understanding Non-Hodgkin Lymphoma primary doctor and ask for a referral to a different specialist if they are not satisfied after their first visit. How to communicate with the healthcare team A good first step is to write down all questions that come to mind. Before meeting with a doctor or nurse, whether for the first time or for follow-up visits, consider organizing these questions to bring to the visit. Put the 2 or 3 most important questions at the top of your list, since time with doctors or nurses may be limited. But make sure that a member of the medical team reads all of your questions, because they may see some that are more important than you realize. Patients should consider having a family member or close friend accompany them to the doctor’s office or clinic to help ask questions and understand and remember answers. A companion could also help by taking notes during the visit. Some patients bring a recording device to record the answers. Check with the patient’s doctor before recording any conversations. Most oncology nurses are also very well informed about cancer treatments and are a good source of information on a wide range of topics. Oncology social workers are also available to assist with practical and emotional needs from the time of diagnosis and onwards. Although family members are often very concerned about their loved one and want information concerning his or her care, confidentiality rules prohibit doctors from giving out information to anyone without the patient’s expressed permission. For efficiency, designate 1 family member as the family contact. The patient must remember to specifically tell the doctor the identity of the primary family contact. Treatment of Non-Hodgkin Lymphoma 42 Part 2 Patients can ease their anxieties by establishing open, honest communication with their doctor and nurse regarding their diagnosis, and learning about what the prescribed treatment regimen is, how it works, what tests are involved, and what side effects and complications may be associated with it. Communicating With Your Doctors At home n Keep a journal of your symptoms to help you remember the details you want to discuss with your doctor during your next office visit. n TIP NT PATIE Make a list of questions that you want to ask your doctor—but if the questions are urgent, do not wait for the next visit; call the doctor’s office to discuss your concerns. At your next doctor’s visit Bring your symptom journal and list of questions, and discuss them with your doctor or nurse. n n n n n n n Ask a family member or friend to come with you to provide emotional support and take notes. Do not be afraid to ask questions if you do not understand something. Your doctor will want to know if you are uncertain or confused, and will be happy to explain things to you. Clarify who should be contacted for specific sorts of questions, or for weekend support. Ask if members of your healthcare team communicate by email. Before leaving the doctor’s office, make sure that you understand the next steps in your care. Ask for written information that you can take home to help you remember what to do, and learn more about your treatment. What is the purpose of an Advance Healthcare Directive and Appointing a Healthcare Proxy? Having an Advance Healthcare Directive (a living will) and appointing a Healthcare Proxy is something that all adults should consider doing regardless of their healthcare status. This is something for everybody to think about, not just people with cancer—accidents and other unforeseen circumstances can happen at any time. 43 Understanding Non-Hodgkin Lymphoma Writing down your wishes for critical medical care in an Advance Healthcare Directive is a way for you to formally tell your doctor, family members, and friends about your healthcare preferences and what special treatments you do or do not want if you were critically ill or injured and unable to make and communicate your own decisions. Part 2 Besides stating medical care instructions, the Advance Healthcare Directive should also include the name of your Healthcare Proxy, or decision maker. This person should be someone you believe will carry out your wishes if you are unable to do so, including any do not resuscitate (DNR) instructions. Before writing an Advance Healthcare Directive, it is important that you understand patients’ rights and laws regarding Advance Healthcare Directives in your state. Consulting an attorney can provide the legal information, but patients do not have to use an attorney to write an advance directive. Make sure that your Advance Healthcare Directive includes: n n Specific instructions on medical care, including the types of special treatment you do or do not want, such as cardiopulmonary resuscitation (CPR), artificial respiration, drugs to make the heart function, kidney dialysis, artificial feeding, and certain surgical procedures. Your choice of a healthcare proxy. For more information about Advance Healthcare Directive guidelines for your state, please visit the “Caring Connections” website of the National Hospice and Palliative Care Organization, at www.caringinfo.org. Treatment of Non-Hodgkin Lymphoma 44 How to be a self-advocate Being a self-advocate and an active participant in your healthcare can be a positive experience and may help restore any sense of control you may have felt was lost following your diagnosis. All patients should remember that they are partners in their treatment plan. Many patients feel better when they actively participate in their care. The first steps in participating in treatment are to ask questions, learn about options, and work closely with the doctor. Patients must be comfortable with their doctor and the approach that they take. If you are not comfortable, you should openly discuss your concerns. Confidence in the medical team often leads to confidence in treatment. If you do not feel that the team is a good match, you should ask for a referral. Questions will likely vary depending on the purpose of the meeting with the oncologist (such as the initial visit to discuss the diagnosis or a routine visit to monitor a remission). Ask for the timing of office visits, treatments, and tests. The doctor can help explain what the tests will look for and define the possible responses and the options for further care depending on treatment response. Although each person is different and each response to therapy is unique, knowing someone who has been through the same treatment and who may have had similar concerns can be a source of great comfort for patients. If you are interested in talking to and learning from people who have had similar experiences, you should ask your oncologist, hematologist, oncology nurse, or the oncology social worker about any support groups in their area. Before you agree to any tests, you should check with your healthcare team to determine which costs are covered by insurance and which are not. You should also not be afraid to talk to your healthcare team about nonmedical issues, such as transportation, finances, insurance, and childcare. 45 Understanding Non-Hodgkin Lymphoma Self-Advocacy n n n Learn more about your specific lymphoma by asking your doctor for information and visiting reliable websites, such as the Lymphoma Research Foundation at www.lymphoma.org. Take advantage of counseling, support groups, nutritional counseling, fitness classes, and other services offered at your doctor’s office, cancer center, or hospital. Part 2 n Do not be afraid to ask your doctor or nurses questions about your care. TIP NT PATIE Consider joining the Lymphoma Support Network, a nationwide buddy program that matches patients and caregivers with people who had similar experiences. For information about the program, call (800) 500-9976 or email [email protected]. Treatment of Non-Hodgkin Lymphoma 46 Part 2 — Treatment of Non-Hodgkin Lymphoma Chapter 6: Treatments for Non-Hodgkin Lymphoma In this chapter, you will learn about the most common therapies that are currently used in the treatment of patients with NHL. Keep in mind that new therapies may have been approved by the United States Food and Drug Administration (FDA) since this book went to print. Read Chapter 10 to learn more about new agents under investigation. What words do doctors use to describe the outcome of treatment? Primary Therapy This is the first therapy that a patient receives. The choice of primary therapy depends on the pathologic characteristics of the disease, including the factors described previously in this booklet. Complete Remission (CR) This term is used when all signs of the lymphoma have disappeared after treatment. This does not mean that the cancer is completely cured; it means that the symptoms have disappeared and the lymphoma cannot be detected using current tests. If this response is maintained for a long period, it is called a durable remission. Cure This word is cautiously used by doctors when there are no signs of the lymphoma reappearing after many years of continuous, complete remission. The term is most often applied to diffuse large B-cell lymphoma or Hodgkin lymphoma. Disease This term means that the disease has worsened or the tumor Progression has grown during therapy. Other terms used to describe this are treatment resistance or resistant disease. Partial Remission (PR) This term is used if the lymphoma has responded to treatment and shrunk to less than one-half of its original size. Improvement This term is used if the tumor has shrunk following therapy but is still more than one-half of its original size. Stable Disease 47 This term means that the disease has not gotten worse or better following therapy (the tumor has not grown or shrunk), but has stayed about the same size. Understanding Non-Hodgkin Lymphoma Refractory Disease This refers to a cancer that is resistant to treatment (meaning that it has not disappeared after treatment). Relapse This term refers to disease that reappears or grows again after a period of remission. What types of treatments are used in patients with NHL? There are 3 general types of therapies for patients with NHL: n n Part 2 n Radiation therapy, which uses high-energy radiation to kill cancer cells. Chemotherapy, which affects general cell growth and division. Biological therapy, which works with the body’s normal functions (such as the immune system) to fight cancer. These therapy types are described in detail throughout the chapter. What is watchful waiting? With the watchful waiting approach, patients do not receive any antilymphoma treatments but their health and disease are monitored through regular checkup visits and follow-up evaluation procedures, such as laboratory and imaging tests. These patients continue to remain untreated as long as they do not have any symptoms and there is no evidence that the lymphoma is growing or spreading. Doctors recommend watchful waiting for selected patients with indolent lymphoma. This approach may be started after the initial diagnosis or after relapse, depending on the situation. Active treatment is started if the patient begins to develop lymphoma-related symptoms or if there are signs that the disease is progressing. Watchful waiting is not a treatment option for patients with aggressive lymphomas. Usually, treatment for these patients should start as soon as possible after diagnosis. Treatment of Non-Hodgkin Lymphoma 48 Questions to Ask Before Starting Watchful Waiting n What happens if I choose watchful waiting and then change my mind? n Will the disease be harder to treat later? n How often will I have checkups? n TIP NT PATIE Between checkups, what symptoms and other problems should I report? What is chemotherapy? Chemotherapy drugs work against general characteristics of cancer cells such as their tendency to grow and multiply very quickly. Depending on the drug, patients may have to swallow a pill or receive it through a liquid infused directly into a vein (intravenous infusion or IV). A few chemotherapy drugs have to be injected in the space around the spinal cord, using a lumbar puncture. During chemotherapy, patients receive the drug or drugs 1 or more times a week for 1 or more weeks, followed by a rest period. This regular treatment schedule is called a cycle. The length of the rest period and the number of cycles vary depending on your disease and the type of drugs used. Most patients with NHL are treated with combination chemotherapy, meaning 2 or more drugs, instead of a single drug. These chemotherapy drugs are given in a specific order (or schedule) during certain days of each treatment cycle—this is called a treatment regimen. The reason to combine drugs is to increase how effectively they kill or damage cancer cells. Oncology nurses are usually responsible for administering the chemotherapy regimen prescribed by the doctor. Most patients receive their chemotherapy in an outpatient clinic, hospital outpatient 49 Understanding Non-Hodgkin Lymphoma department, or doctor’s office, but sometimes patients have to stay in the hospital for their treatment. Common chemotherapy regimens for non-Hodgkin lymphoma Regimen Abbreviation Common Treatment(s) B Bendamustine (Treanda) C Cyclophosphamide (Cytoxan) Chl Chlorambucil (Leukeran) CVP (COP) Cyclophosphamide (Cytoxan) Vincristine (Oncovin, Vincasar PFS) Prednisone (Deltasone) CHOP Cyclophosphamide (Cytoxan) Doxorubicin/hydroxydaunorubicin (Adriamycin, Rubex) Vincristine (Oncovin, Vincasar PFS) Prednisone (Deltasone) DHAP Dexamethasone (Decadron) Cytarabine (Cytosar, DepoCyt, Tarabine PFS) Cisplatin (Platinol, Platinol-AQ) Treatment of Non-Hodgkin Lymphoma 50 Part 2 Many of these regimens can also include the monoclonal antibody rituximab (Rituxan) which is abbreviated by the letter R, usually at the beginning or end of the regimen abbreviation (such as R-CHOP or CHOP-R). Most of these chemotherapy drugs have been in use for decades, but several have been developed more recently. Bendamustine (Treanda) is a novel alkylating agent, a class of drugs that cause damage to a cell’s DNA. Pralatrexate (Folotyn) is a novel antimetabolite, a class of drugs that interfere with normal DNA production. Since cancer cells divide more rapidly than normal cells, they are more sensitive to DNA damage. Bendamustine was approved in 2008 for the treatment of chronic lymphocytic leukemia and for NHL that has progressed after treatment with a rituximab-containing regimen. Pralatrexate was approved in 2009 for the treatment of peripheral T-cell lymphoma that has progressed after prior treatment. Both drugs are also being investigated for other uses. EPOCH Etoposide (VePesid, Etopophos, Toposar) Prednisone (Deltasone) Vincristine (Oncovin, Vincasar PFS) Cyclophosphamide (Cytoxan) Doxorubicin/hydroxydaunorubicin (Adriamycin, Rubex) ESHAP Etoposide (VePesid, Etopophos, Toposar) Methylprednisolone (Solu-Medrol) Cisplatin (Platinol, Platinol-AQ) Cytarabine (Cytosar, DepoCyt, Tarabine PFS) FC Fludarabine (Fludara) Cyclophosphamide (Cytoxan) FND Fludarabine (Fludara) Mitoxantrone (Novantrone) Dexamethasone (Decadron, Dexasone) GDP Gemcitabine (Gemzar) Dexamethasone (Decadron, Dexasone) Cisplatin (Platinol, Platinol-AQ) GemOX Gemcitabine (Gemzar) Oxaliplatin (Eloxatin) HyperCVAD/ MTX-Ara-C Cyclophosphamide (Cytoxan) Vincristine (Oncovin, Vincasar PFS) Doxorubicin/hydroxydaunorubicin (Adriamycin, Rubex) Dexamethasone (Decadron) Methotrexate (Rheumatrex) Cytarabine (Cytosar, DepoCyt, Tarabine PFS) ICE Ifosfamide (Ifex) Carboplatin (Paraplatin) Etoposide (VePesid, Etopophos, Toposar) MINE Mesna (Mesnex) Ifosfamide (Ifex) Mitoxantrone (Novantrone) Etoposide (VePesid, Etopophos, Toposar) P Pralatrexate (Folotyn) 51 Understanding Non-Hodgkin Lymphoma How is chemotherapy given? Type of Catheter Description Advantages Disadvantages A needle is used to insert a small flexible tube (the catheter or cannula) into a vein in the hand or arm. Drugs and other fluids are given through the various types of attachments. No need for surgical insertion. A good option for patients who require few infusions spaced wide apart. Sterile dressing needs to be kept clean and dry and replaced daily; the line needs to be injected periodically with a blood thinner (heparin) to prevent blockage. To minimize the risk of infections, the catheter needs to be replaced at least every 3 days or sooner if it becomes blocked. Cannot be used to draw blood for blood tests. Hickman Consists of 1-3 and Broviac tubes surgically inserted through the subclavian vein (the vein that runs underneath the collar bone) in the chest wall into a vein. Six to 12 inches of tubing remain outside the skin. It makes it easy to draw blood and give drugs using standard needles and without having to pierce the skin. Requires proper care to reduce the risk of infection and blockage. The tubes on the outside of the body make it more obvious that a catheter is in place. Patients need training and instructions to learn to clean and take care of the external tubes. Peripheral Venous Catheter Treatment of Non-Hodgkin Lymphoma 52 Part 2 Depending on the regimen, patients will be given chemotherapy in pill form, as an injection, or as an intravenous (IV) drip through a vein. To make it easier to give and receive multiple cycles of chemotherapy by IV, the doctor may insert an IV catheter or port that will stay in place for a few weeks or for the duration of the chemotherapy treatment. There are several types of these catheters, described in the following chart. Patients should discuss with their doctor which catheter, if any, would be best for their particular situation. Infusaport A catheter is or Portacath surgically inserted through the subclavian vein and attached to a small reservoir (port) that lies under the skin. Nothing is visible on the outside except for a bump on the chest. Patients do not have to do anything to care for it; once a month a nurse keeps the line open by “flushing” with a small amount of injected liquid. The patient must be injected through the skin with a special needle each time it needs to be used. Sometimes it is hard to use it to draw blood samples because of clogging (due to a blood clot). Peripherally Inserted Central Catheter (PICC line) A good option for patients who only need to have many short infusions or continuous infusions given in a hospital or at home with a portable pump. This is more temporary than the other types of catheters. A thin, soft plastic tube is inserted in a large vein in the arm. Why is it important to adhere to the chemotherapy treatment schedule? Patients should adhere to the chemotherapy treatment schedule because a full course of chemotherapy works best in the treatment of their disease. In clinical studies, doctors have found that reducing the dose or delaying chemotherapy may decrease the chance of a cure or long-term survival for patients with certain types of lymphomas. Changing the regimen to reduce short-term side effects may actually be harmful in the long run. Some side effects may be unpleasant but tolerable (see Part 3, “Side Effects and Living With Cancer”). Other side effects may be serious but can often be anticipated and prevented. It is very important that chemotherapy schedules be maintained to the greatest extent possible. What is radiation therapy? Radiation therapy (also called radiotherapy) uses high-energy x-rays or other types of radiation to kill cancer cells and shrink tumors. The term is used typically to describe external radiotherapy, in which 53 Understanding Non-Hodgkin Lymphoma radiation is delivered using an external radiation beam; however, certain drugs can also deliver radioactive molecules directly to tumor cells (see page 58, “What is radioimmunotherapy?”). To prepare for radiation therapy, the healthcare team will precisely mark the patient’s body with tiny ink dots (called tattoos) to make sure that only the targeted areas receive radiation. During the day of treatment, they will use lead shields to protect a patient’s normal tissues around the radiation field. They use plastic forms, pillows, and rolled blankets to make the patient comfortable and keep him or her in the proper position. Patients need to lie still on a table beneath a large machine that delivers the radiation painlessly. Once the preparations have been made, it takes only a few minutes to deliver the prescribed dose. The total dose of radiation is usually divided and given over 1-6 weeks. During and after the radiation treatment, patients will have to carefully protect the radiation site from the sun. Treatment of Non-Hodgkin Lymphoma 54 Part 2 A radiation oncologist will be in charge of your radiation therapy. The part of the body selected to receive the radiation therapy is called the radiation field. Doctors usually limit the radiation field to affected lymph nodes, the areas immediately surrounding lymphoma nodes, or other non-lymph node areas where the lymphoma started. Doctors will decide on the type and size of the radiation field depending on the type of tumor and the extent of disease. Some of the more common types of radiation therapy and delivery methods used for NHL include: Electron Beam (EB) Radiation Intensity-Modulated Radiation Therapy (IMRT) n n n n n Total Skin Electron Beam Radiation Therapy (TSEBT) n n Photopheresis or Extracorporeal Photochemotherapy n n n n 55 In this form of radiation therapy, a machine is used to send electrons, or negatively charged particles, directly to the area where the lymphoma is found and, potentially, to nearby lymph nodes. In this form of radiation therapy, different doses of radiation are directed toward the cancer site using radiation beams of varying intensities. First, a 3-dimensional image of the tumor is collected using CT, MRI, or PET scans. Then, a special computer program analyzes the 3-dimensional image and designs radiation beams specific to the shape of the tumor. With this technique, doctors target the tumor with radiation, while reducing exposure to the healthy tissue surrounding it. This is often used for the treatment of patients with cutaneous T-cell lymphoma (CTCL), which is a form of lymphoma that occurs on the outermost layers of skin. TSEBT directs radiation to the entire surface of the body, but because the radiation is weak it only penetrates the outer layers of the skin. The deeper layers of skin and other tissues are not exposed to radiation. In this form of therapy, doctors remove a fraction of the patient’s blood and treat it with a chemical that makes lymphocytes more likely to die when exposed to ultraviolet A light. The blood is exposed to this ultraviolet light and reinfused back into the patient. This form of therapy has been approved by the FDA for the treatment of cutaneous T-cell lymphoma. It may also be effective in the treatment of graft-versushost disease, a common complication following donor stem cell transplantation. Understanding Non-Hodgkin Lymphoma Questions to Ask Before Starting Radiation Therapy n What is the goal of my radiation therapy? n How will the radiation be given? n When will treatment begin? When will it end? n How will I feel during the therapy? n n What are the side effects of radiation therapy? Is there anything that can be done to prevent them? Part 2 n TIP NT PATIE Are there any lasting effects? What can I do to take care of myself during and after the therapy? n How will we know if the radiation therapy is working? n How will the radiation treatment affect my normal activities? What other types of drugs are used to treat patients with non-Hodgkin lymphoma? In addition to chemotherapy and radiation therapy, there are many types of other drugs used to treat NHL. These include monoclonal antibodies, immunoconjugates, radioimmunotherapy, fusion toxins, proteasome inhibitors, and histone deacetylase (HDAC) inhibitors. Most of these drugs have been developed relatively recently. Other types of drugs may have been approved by the FDA since the time this booklet was printed. What are monoclonal antibodies? As part of our immune system, specialized white blood cells called plasma cells make proteins called antibodies. Antibodies help fight infection by recognizing and sticking to anything that the body considers “foreign.” Each antibody our body makes is naturally designed to recognize one specific type of molecule. Treatment of Non-Hodgkin Lymphoma 56 Monoclonal antibodies are molecules made in the laboratory that are designed to recognize and stick to specific molecules on, for example, cancer cells. When a monoclonal antibody attaches itself to a cancer cell, it can stop or slow down its growth or it can make it easier for the immune system to recognize it and kill it. The monoclonal antibody rituximab (Rituxan) is approved by the FDA to treat patients with NHL. The monoclonal antibodies alemtuzumab (Campath) and ofatumumab (Arzerra) are approved by the FDA to treat chronic lymphocytic leukemia (CLL). Monoclonal antibody therapies are given to patients as intravenous infusions during visits at the doctor’s office or clinic. See the following sections for additional information about these monoclonal antibodies. What is rituximab? Rituximab (Rituxan) is a monoclonal antibody that recognizes CD20, a specific molecule found on the surface of almost all B cells. In 1997, rituximab became the first monoclonal antibody approved by the United States Food and Drug Administration (FDA) for the treatment of patients with cancer—specifically for the patients with relapsed or refractory lowgrade or follicular, B-cell NHL. As of 2012, rituximab is approved by the FDA for the treatment of patients with NHL, including as maintenance therapy following an initial response to rituximab, and for CLL in combination with fludarabine and cyclophosphamide. Rituximab treatment is given as an intravenous infusion; the schedule varies depending on the type of combination regimen used. When combined with chemotherapy, rituximab is usually given during the first day of each chemotherapy cycle. 57 Understanding Non-Hodgkin Lymphoma The side effects caused by rituximab are usually mild and include chills, fever, nausea, rashes, fatigue, and headaches. Rarer more serious side effects include trouble breathing and low blood pressure, usually during the first infusion. Rituximab treatment can make a person more susceptible to infection during and for up to 6 months after treatment. Because of this, rituximab is not recommended for use in patients with severe, active infections. Alemtuzumab (Campath) is a monoclonal antibody targeting CD52, a molecule found on the cell surface of many lymphoma types. Alemtuzumab is approved specifically for treatment of CLL. Alemtuzumab is given by intravenous infusion, initially at a low dose every day and gradually increased in dose depending on how well it is tolerated. Possible side effects are similar to those for rituximab. What is ofatumumab? Ofatumumab (Arzerra) is a monoclonal antibody that, like rituximab, targets CD20. Ofatumumab is approved for patients with CLL who are refractory to both fludarabine (Fludara) and alemtuzumab. Ofatumumab is also administered by intravenous infusion every week for 8 weeks followed by 4 additional doses every 4 weeks. Possible side effects include many in common with other monoclonal antibodies. What is radioimmunotherapy? In radioimmunotherapy, a radioactive molecule is attached to a monoclonal antibody to deliver small amounts of radiation therapy directly to the cells that the monoclonal antibody recognizes. If you are to be treated with radioimmunotherapy, your doctor will talk to you about any necessary safety precautions. While there are differences in scheduling, doses, and side effects, patients treated with radioimmunotherapy usually have to undergo imaging tests, 2-4 injections of the radioimmunotherapy drugs, and close monitoring of blood counts for several weeks during and after treatment. Treatment of Non-Hodgkin Lymphoma 58 Part 2 What is alemtuzumab? The radioimmunotherapeutic monoclonal antibodies ibritumomab tiuxetan (Zevalin) and tositumomab (Bexxar) are used to treat patients with indolent NHL. Similar to rituximab, both of these drugs target CD20 expressing B cells. Ibritumomab tiuxetan consists of the monoclonal antibody ibritumomab linked to tiuxetan, a specialized molecule (called a chelator) that is bound to the radioactive element yttrium-90. The ibritumomab component of the drug specifically binds to NHL B cells that express CD20. Once bound, the radioactive emissions from yttrium-90 damage the cell, triggering its destruction. Ibritumomab tiuxetan first received approval by the US FDA in 2002. It is approved to treat patients with the following types of diseases: n n Relapsed or refractory, low-grade, or follicular B-cell NHL. Newly diagnosed follicular NHL who achieve partial or complete response to first-line chemotherapy. Ibritumomab tiuxetan is given through an intravenous injection in combination with 2 rituximab treatments. The most common toxicities associated with this treatment include low blood cell counts, tiredness, stomach pain, nausea, inflammation of the nose and upper throat, weakness, diarrhea, cough, and fever. Tositumomab consists of a monoclonal antibody chemically linked with the radioactive element iodine-131. Tositumomab also recognizes and binds to CD20. This drug first received US FDA approval in 2003. It is approved to treat patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed NHL (including patients whose disease has not responded to rituximab treatment). The most common toxicities associated with this treatment include low blood cell counts, infections, infusion site reactions, weakness or lack of energy, fever, and nausea. 59 Understanding Non-Hodgkin Lymphoma What is brentuximab vedotin? Brentuximab vedotin received approval by the FDA in 2011 for the treatment of patients with the following: n n Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least 2 previous combination chemotherapy regimens in patients who are not candidates for autologous stem cell transplant. Systemic anaplastic large cell lymphoma after failure of at least 1 previous combination chemotherapy regimen. Patients receive brentuximab vedotin as an intravenous infusion, given once every 3 weeks. The most common side effects reported in patients treated with this drug include a depressed immune system, low blood counts, peripheral sensory neuropathy (a numbing of hands or feet), fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, fever, rash, cough, and vomiting. Treatment of Non-Hodgkin Lymphoma 60 Part 2 Brentuximab vedotin (Adcetris) is an immunoconjugate; it is a combination of a monoclonal antibody against CD30 (brentuximab) attached to the small toxic drug monomethyl auristatin E (vedotin or MMAE). The monoclonal antibody part of this drug attaches itself to lymphoma cells that express CD30, causing them to transport the drug into the cells. Once inside cells, the MMAE drug is separated from the antibody molecule. The MMAE attacks and breaks up an internal support skeleton (called the microtubule network) of the cells, causing them to stop dividing and die. What is bortezomib? Bortezomib (Velcade) is a proteasome inhibitor; these are a class of drugs that inhibit the ability of cells to properly dispose of proteins. Proteasome inhibition causes an abnormal build-up of proteins in a cancerous cell, resulting in cell death. Bortezomib was the first proteasome inhibitor developed, and was first approved in 2003 for the treatment of multiple myeloma. Bortezomib was subsequently approved in 2006 for the treatment of relapsed mantle cell lymphoma, a type of NHL, and is being studied for other NHL types as well. What are histone deacetylase inhibitors? Histone deacetylase (HDAC) inhibitors are drugs that interact with chromosomes in such a way to trigger the production of proteins that normally would have been blocked by the cell. HDAC inhibitors typically result in a cancer cell expressing proteins that interfere with its ability to grow and survive. Currently there are 2 HDAC inhibitors approved for the treatment of NHL: romidepsin (Istodax), approved for the treatment of relapsed cutaneous T-cell lymphoma and peripheral T-cell lymphoma, and vorinostat (Zolinza), approved for the treatment of relapsed or refractory cutaneous T-cell lymphoma. What is maintenance therapy? Maintenance therapy refers to the ongoing treatment of patients whose disease has responded well to first-line treatment. The purpose of maintenance therapy is to make it less likely that the cancer will come back and to help to keep a more aggressive cancer that has stopped growing from restarting to grow and spreading to other parts of the body. Maintenance therapy typically consists of drugs given at lower doses and longer intervals than when they are given during initial therapy. Depending on the type of NHL and the drugs used, maintenance therapy may last for weeks, months, or even years. Common drugs for use as maintenance therapy include rituximab, which is approved for 61 Understanding Non-Hodgkin Lymphoma NHL maintenance therapy following an initial response to rituximab, and the immunomodulatory drug lenalidomide (Revlimid), which is currently under investigation for NHL treatment (see Chapter 10, “Advances in Treatment of Patients With Non-Hodgkin Lymphoma”). Questions to Ask About Maintenance Therapy Is maintenance therapy an option for me? n Why are you recommending maintenance therapy? n What are the benefits and risks? n How often and for how long will I receive this treatment? n Does my insurance cover this treatment? n Part 2 n TIP NT PATIE Is this better for me than watchful waiting (checking for recurrence, with no treatment)? What are complementary and alternative remedies? Alternative therapy refers to treatments that are used instead of standard therapy recognized as effective by the medical profession. Currently, there are no proven alternative therapies to conventional cancer care for patients with NHL. Patients should not use alternative remedies to replace the standard care suggested by their doctors. Complementary therapy is used in addition to standard medicine to help improve a patient’s quality of life and to relieve the effects of chemotherapy, radiation, and surgery. Patients should talk to their doctor before starting any form of complementary therapy because some of these practices can make cancer treatment less effective. Treatment of Non-Hodgkin Lymphoma 62 Complementary therapy, also known as integrative medicine, includes the following varied forms of therapy: Mind/Body Therapies n n n Touch Therapies n n n Acupuncture n n Nutrition n Examples: meditation, guided imagery, self-hypnosis, Tai Chi, yoga. Meditation, guided imagery, and self-hypnosis can help manage stress. Yoga and Tai Chi minimize stress and improve balance and flexibility. Examples: massage, reflexology (foot massage), Reiki, etc. These techniques apply therapeutic pressure to the body to restore a sense of harmony, relaxation, and well-being. Studies suggest that massage may lessen pain. Some studies show that acupuncture may relieve pain, nausea, fatigue, hot flashes, and neuropathy (numbness and tingling in the feet and hands) associated with chemotherapy and may help decrease mild depression. Using ultra-thin needles applied to specific points on the body, acupuncture is safe and painless. Needles used should be disposed of and only used once. Patients undergoing lymphoma treatment should eat a healthy, well-balanced diet that contains 5-7 servings of fruits and vegetables a day, fish or poultry, and whole grains. What is relapsed or refractory non-Hodgkin lymphoma? Relapsed NHL means that the disease has returned after responding to treatment—this is sometimes also called a recurrence. Refractory NHL means that the patient’s disease no longer responds to a specific treatment. There are many treatment options for patients with relapsed or refractory lymphomas. Exactly what type of treatment is optimal for individual patients with relapsed or refractory lymphoma depends on factors such as the type of lymphoma, age, extent of disease, overall health, and previous therapies received. Most combination chemotherapies already discussed can be effective in patients with relapsed or refractory lymphoma. Rituximab (Rituxan) may be used in combination with many of these chemotherapy regimens. 63 Understanding Non-Hodgkin Lymphoma The radioimmunotherapy drugs ibritumomab tiuxetan (Zevalin) and tositumomab (Bexxar) are also used in patients with relapsed disease. Many centers will consider using autologous or allogeneic transplantation for patients with relapsed or refractory NHL. Sequential transplantations are possible if the disease continues to return or does not fully respond. Part 2 Patients who do not go into complete remission following treatment or who do not respond to treatment should not lose hope. Complete remission may be achieved following a diagnosis of relapsed or refractory disease. Many patients seek second opinions at any point from diagnosis onward and often choose to do so if their disease relapses or is considered refractory. Many of the novel therapeutic agents most recently approved by the FDA and those being investigated in clinical trials are used specifically for patients with relapsed or refractory disease. Lymphoma research continually evolves as doctors and scientists discover new therapies and more effective ways of giving existing treatments. Chapter 10 describes some of the options currently under investigation. When should a clinical trial be considered? Clinical trials are appropriate for patients at all stages of disease (see Chapter 9, “Overview of Clinical Trials”). The purpose of a clinical trial is to safely monitor the effects of a drug on patients over time and to identify more effective therapies for specific diseases. By participating in a clinical trial, patients may or may not get access to the newest therapies but will receive quality care in a very carefully controlled and supportive environment. Participation in a clinical trial is especially important for patients with NHL because many of the different lymphoma types are rare diseases, which make it very hard to find enough patients to enroll in studies. If patients are interested in participating in a clinical study, they should ask their doctor if there is an appropriate trial for them and what the potential risks and benefits may be. Treatment of Non-Hodgkin Lymphoma 64 What is stem cell transplantation? There are different types of stem cell transplantation, depending on who donates the stem cells. In an autologous stem cell transplant, the patient is the donor. In an allogeneic stem cell transplant, the donor is another person who is genetically similar to the patient—typically a brother or sister, but the donor can also be an unrelated person. The purpose of autologous or full-intensity allogeneic stem cell transplantation is to allow patients to receive high-dose chemotherapy. Such high doses effectively kill cancer cells but also severely damage the bone marrow as a side effect, destroying the body’s source of blood cells responsible for fighting infection, preventing bleeding, and carrying oxygen. A stem cell transplantation re-populates the stem cells responsible for making these blood cells. Because high-dose therapy and stem cell transplantation place great strain on a patient’s body, they are not options for everyone. In deciding if transplantation is a good option, doctors will consider the patient’s health status, age, medical history, cancer stage, and response to previous therapy. 65 Understanding Non-Hodgkin Lymphoma ALLOGENEIC STEM CELL TRANSPLANTATION Stem cell transplantation using stem cells from a donor who is genetically similar to the patient. 2. Processing Blood or bone marrow may be processed in the laboratory to purify and concentrate the stem cells. Donor 3. Infusion Stem cells are infused into the patient. Part 2 1. Collection Stem cells are collected from the donor’s bone marrow or blood. Patient AUTOLOGOUS STEM CELL TRANSPLANTATION Stem cell transplantation using a patient’s own stem cells. 1. Collection Stem cells are collected from the patient’s bone marrow or blood. 2. Processing Blood or bone marrow may be processed in the laboratory to purify and concentrate the stem cells. Samples are frozen until needed. 3. Reinfusion Stem cells are thawed and reinfused into the patient. Patient Treatment of Non-Hodgkin Lymphoma 66 Reduced-intensity transplantation (also called non-myeloablative or mini-allogeneic transplantation) uses lower doses of chemotherapy and/or radiation prior to allogeneic transplantation. This option is available only for allogeneic transplantation and cannot be used for autologous transplantation. This approach takes advantage of the graft-versus-disease effect, in which the transplanted cells (the “graft”) recognize the cancerous cells in the patient’s body as foreign and destroy them. Patients receiving reduced-intensity transplants may avoid some of the side effects seen with higher-dose chemotherapy, although they still have increased risks of serious side effects as compared with autologous stem cell transplantation due to the potential for graft-versus-host disease (in which immune cells in the transplant recognize the patient cells as “foreign” and attack them). Questions to Ask Before Deciding to Undergo Stem Cell Transplantation n What type of transplantation is most appropriate for me? n Why do you think this is a good idea? n What are the risks associated with this procedure? n Why do you recommend this particular type of transplantation? n If I need a donor, how will I find one? n How long will I need to be in the hospital? n What type of special care will I receive? n How sick will this treatment make me? n What will you do to lessen the side effects? n How will we know if the treatment is working? n n 67 How and for how long will the treatment affect my normal activities? What is my chance of making a full recovery? Understanding Non-Hodgkin Lymphoma TIP NT PATIE For more information on transplantation, please visit the “Be the Match” website at www.bethematch.org. Drug costs: What to do if insurance will not pay Patients in need of financial assistance should talk with their doctor and social worker about available options and how to enroll in an appropriate program. Before undergoing a medical procedure, patients should check with their insurance carrier to ensure that it is covered. If there is a dispute about coverage or if coverage is denied, patients should ask their insurance carrier about its appeals process. Contact your state’s department of insurance if a claim is denied. Treatment of Non-Hodgkin Lymphoma 68 Part 2 Many patients today face the problem of how to pay for rising healthcare costs. Cancer organizations like the Lymphoma Research Foundation (www.lymphoma.org) offer limited financial assistance to patients who qualify. Most pharmaceutical/biotechnology companies have patient assistance programs in place that provide drugs for free to qualifying patients. Part 3 — Side Effects and Living With Cancer Chapter 7: Common Treatment Side Effects Patients with NHL may experience various side effects or toxicities caused by their cancer treatment. Fortunately, medications and lifestyle changes can effectively prevent or lessen the severities of most of these side effects. Patients should ask their healthcare team about possible treatment side effects and how to prevent and manage them and tell their doctor or nurse if they experience any side effects. This chapter explains the causes of these side effects, the types of side effects caused by different treatments, and steps to take to minimize these side effects. Why does chemotherapy cause side effects or toxicities? Chemotherapy drugs cause side effects because of the non-specific way these drugs attack cancer cells. Most chemotherapy drugs are designed to kill cells like cancer cells that divide rapidly (meaning that they are multiplying quickly). Most normal cells in the body do not divide as quickly as cancer cells. However, healthy cells in hair roots, and cells in the mouth, gastrointestinal tract, and the bone marrow do divide rapidly and can be killed or damaged by chemotherapy. Some chemotherapy drugs can also damage heart or lung cells. The type and severity of side effects caused by chemotherapy vary widely depending on the types of drugs that are given and an individual patient’s response. The same drug may cause no side effects in one patient, while in others it may cause anything from very mild to very serious side effects. What is the difference between long-term effects and late effects? Long-term effects are toxicities that happen during cancer treatment and continue for months or several years. Fatigue, menopausal symptoms, infertility, and lung problems are examples of long-term effects. 69 Understanding Non-Hodgkin Lymphoma Late effects of treatment become apparent only after treatment has ended and may arise many months, years, or even decades after treatment is completed. Cardiovascular problems, osteoporosis, and secondary cancers (such as lung cancer) are examples of late effects. The combination of the chemotherapy drug doxorubicin (Adriamycin) and radiation, especially when the radiation is directed to the chest area, can lead to late effects to the heart, causing a decrease in cardiac function and accelerated atherosclerosis in which plaque builds up on the inside of the arteries. What side effects are caused by chemotherapy? Part 3 Note that side effects vary depending on the type of chemotherapy; additionally, these adverse effects can have causes other than chemotherapy. Some of the most common side effects include: n Changes in taste. n Decreased blood cell production. n Increased chance of infections. n Fatigue. n Hair loss. n Loss of appetite. n Mouth sores. n Nausea and vomiting. n Problems with sexual function. n Cognitive problems (trouble concentrating, impaired memory). n Peripheral neuropathy. Side Effects and Living With Cancer 70 Changes in taste Some patients will experience a change in the way foods or beverages taste. Familiar foods may taste differently (dysgeusia) or the flavors of foods may not be as strong (hypogeusia). Some patients may also feel that foods have a metallic taste. These side effects are temporary and usually disappear after the end of chemotherapy. Decreased blood cell production The bone marrow constantly produces red blood cells, white blood cells, and platelets. Some types of chemotherapy and immunotherapy temporarily interfere with the ability of the bone marrow to produce enough of 1 or more of these different types of blood cells. This is called myelosuppression. To prevent and control myelosuppression, samples of a patient’s blood are tested for: complete blood count (CBC), which measures the number of red blood cells; differential, which measures the amounts of different types of white blood cells; and the number of platelets. These tests are usually done before and sometimes during each chemotherapy cycle. There are 3 main conditions caused by decreased production of blood cells: Anemia n n n 71 This is caused by a decrease in the number of red blood cells. Many chemotherapy drugs cause mild or moderate anemia. Anemia can make people feel very tired and short of breath; if needed, anemia can be treated with drugs or red blood cell transfusions. Understanding Non-Hodgkin Lymphoma Neutropenia n n n n Thrombocytopenia n n n Patients with low neutrophil count are at risk of serious and even life-threatening infections—symptoms of infection include fever, chills, and night sweats. A normal white blood cell count ranges from 4,000-10,000 cells per microliter. Doctors regularly monitor the absolute neutrophil count (ANC), the number of neutrophils in the peripheral blood. Because patients with an ANC below 500 are at high risk for infections, their doctors may decrease the chemotherapy dosage or delay the next treatment in order to keep the ANC above 500. Some patients require treatment with antibiotics and hospitalization to prevent or treat infections. Part 3 n Neutropenia refers to a decrease in neutrophils—the primary type of white blood cells that fight infection. To avoid a patient missing a dose of chemotherapy, doctors sometimes prescribe drugs like filgrastim (Neupogen) and pegfilgrastim (Neulasta) to reduce the duration and severity of neutropenia. These drugs can sometimes cause bone pain which can be relieved with nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen. Thrombocytopenia refers to a decrease in the number of platelets in the blood; platelets help start the clotting process when bleeding occurs. Patients with low platelet counts may bruise easily; have cuts that bleed for too long or too much; have nose bleeds or bleeding gums; or may bleed from places that have not been injured. Some patients require a platelet transfusion to stop or prevent bleeding. Side Effects and Living With Cancer 72 TIP NT PATIE Reducing Your Risk of Serious Infection During Chemotherapy n n If you have a fever of 100.5°F or greater, call your doctor or go to the emergency room. Ask your doctor what you should do if you have a sore throat, rash, diarrhea, a cough, or redness, swelling, or pain around a wound. Fatigue Fatigue is a common side effect of many types of chemotherapy. Fatigue should decrease after patients have completed their lymphoma treatment, but it could take weeks or months until they return to their normal energy levels. Coping With Fatigue n n n n 73 Keep a diary to help you keep track of when you have the most energy and which activities make you feel tired or give you energy. Use this information to plan your activities for the times when you have the most energy. Ask for help. Exercise if your doctor says it is okay to do so, but do not overdo it. Try simple stretching and range-of-motion exercises or a short walk; these may energize you without tiring you out. Start slowly and build up to the level that is right for you. Ask your doctor, nurse, or physical therapist to help you create a personal exercise plan. Rest and sleep during therapy are very important, but do not rest more than you need because it may decrease your energy levels. An afternoon nap helps many patients feel less tired for the rest of the day. Other patients cannot sleep at night if they nap during the day. If you have trouble sleeping, talk to your healthcare team to find out why and what you can do about it. Understanding Non-Hodgkin Lymphoma TIP NT PATIE Hair loss Certain chemotherapy drugs can cause thinning or loss of hair (alopecia) anywhere in the body, including the scalp, eyebrows, eyelashes, arms, legs, and pelvis. The amount of hair loss may vary. If hair loss occurs, it often starts 2 or 3 weeks after the first chemotherapy treatment. Remember that hair loss caused by chemotherapy is usually temporary. Hair will probably grow back after the end of chemotherapy treatments. When the hair first grows back, it may have a slightly different texture or color than it had before treatment. Over time, the texture and color often return to normal. n After washing it, pat your hair dry instead of rubbing it with a towel. n Brush your hair with a soft-bristle brush or a wide-tooth comb. n Do not use curlers and hair dryers. n Do not color or perm your hair, or treat it with other chemicals. n n Consider using a wig, scarf, turban, soft cotton hat, or head wrap. Some health insurance companies cover the cost of wigs if you have a doctor’s prescription. Check your policy to see if it covers this cost. Use a hat or scarf to protect your scalp when you are out in the sun. Side Effects and Living With Cancer 74 Part 3 Managing Chemotherapy-Induced Hair Loss TIP NT PATIE Mouth sores Some chemotherapy drugs can make a patient’s mouth become red, sore, or irritated—this is called mucositis. Some patients undergoing chemotherapy become more susceptible to viral or fungal infections of the mouth and throat. Patients should tell their doctor if they have a sore throat. The doctor will examine the patient’s throat and may take a swab to send to the lab to check for infection. Several medications are available to treat different types of infections. To help decrease chances of infection, patients should have a complete dental checkup and cleaning before starting chemotherapy. Preventing and Caring for Mouth Sores n n n n n n 75 Clean your mouth and teeth. Use a soft-bristle toothbrush, nonabrasive toothpaste, and lip moisturizer. Do not use mouthwashes that contain alcohol. Your doctor or nurse may recommend a mouth rinse. Do not eat citrus fruits (such as oranges, grapefruit, lemons, or clementines) or drink citrus juices. Do not eat spicy foods. Eat soft foods while you are taking chemotherapy to avoid bruising your gums and other soft tissues in your mouth. Do not floss your teeth if your blood counts are low. Understanding Non-Hodgkin Lymphoma TIP NT PATIE Nausea or vomiting Some chemotherapy drugs can cause nausea or vomiting, usually on the day chemotherapy is administered but sometimes 1 or 2 days later. Your doctor may prescribe a drug that prevents vomiting (antiemetic) before chemotherapy. Examples of antiemetics include: aprepitant (Emend), ondansetron (Zofran), granisetron (Kytril), metoclopramide (Reglan), prochlorperazine (Compazine), and dolasetron (Anzemet), and a variety of corticosteroids, such as prednisone (Deltasone). In most cases, these antiemetics are able to partially or completely prevent nausea and vomiting. n n n n n n Part 3 Controlling or Minimizing Nausea and Vomiting TIP NT PATIE Before chemotherapy, drink a liquid diet, such as broth, consommé, or water. Do not drink milk. Do not eat foods that are too hot, cold, sweet, or spicy. Eat smaller and more frequent meals instead of fewer large meals each day. Avoid strong or offensive smells. Get plenty of fresh air. Take prescribed antiemetics before chemotherapy to prevent nausea. If you vomit, make sure to avoid becoming dehydrated. Side Effects and Living With Cancer 76 Diarrhea Some types of chemotherapy cause diarrhea. While most patients do not experience severe diarrhea, the most important thing to remember is to avoid dehydration, a loss of body fluids. Call your doctor if you have bloody diarrhea or fever with diarrhea. Avoiding Dehydration From Diarrhea or Vomiting n n n n n n TIP NT PATIE Drink plenty of liquids (8 glasses a day) such as water or electrolyte replacement drinks like Gatorade and Powerade. Look for the following signs of dehydration: dry mouth or skin, decreased urine, or feeling dizzy or lightheaded when you stand up. Do not drink or eat milk products because they worsen diarrhea. Do not eat high fiber and other hard to digest foods because they can worsen diarrhea. Eat plenty of bananas and other high-potassium food (check with your doctor or dietitian to make sure that these foods will not interfere with your chemotherapy or other medications that you are taking). Take the medicines that your doctor recommends to control diarrhea or vomiting (call your doctor if symptoms persist). Problems with sexual function Chemotherapy can cause a drop in the sex drive (libido). Usually, a normal libido returns after treatment is finished. Patients should not be embarrassed to talk with their doctor about any problems or concerns they have about changes in their libido. 77 Understanding Non-Hodgkin Lymphoma Sterility Since chemotherapy and radiation may damage sperm and egg cells, it can sometimes cause temporary or permanent sterility, or the inability to have children, in both men and women. The potential for developing sterility depends on the treatment type and specific dose, the number of therapies given, and the patient’s age at the time of treatment. Patients should speak with their doctor about fertility preservation (such as treatments to protect the ovaries or cryopreservation of sperm cells, egg cells, or in vitro-fertilized embryos) before starting treatment. For more information and resources about sterility, visit the website for Fertile Hope at www.fertilehope.org. Chemotherapy can result in mild cognitive impairment such as trouble concentrating, impaired memory, or issues with motor control. While such symptoms can be distressful, they typically disappear over time. Peripheral neuropathy Some chemotherapy drugs may also cause damage to the nervous system called peripheral neuropathy. Nerve damage can cause side effects such as constipation or a tingling sensation in the fingers and toes. Cardiotoxicity Cardiotoxicity refers to damage to cells in the heart or heart muscle. Long-term use of certain chemotherapy drugs can cause heart damage in some patients. Doxorubicin is an example of a drug that is possibly cardiotoxic. In general, most patients with NHL treated with potentially cardiotoxic chemotherapy receive these drugs at dose levels and numbers of cycles where cardiac toxicity is usually not a problem. For example, many patients with diffuse large B-cell lymphoma only need to be treated with chemotherapy once; therefore, their risk for developing chemotherapy-related cardiovascular disease is small. Side Effects and Living With Cancer 78 Part 3 Cognitive problems A person’s history of heart disease, high cholesterol and high blood pressure, and obesity and lifestyle choices such as smoking and lack of exercise may increase their chance of developing chemotherapyrelated or radiation-related cardiotoxicity. Careful monitoring by the patient’s healthcare team can reduce the chances of developing cardiotoxicity. Before deciding to treat patients with a cardiotoxic drug, most doctors will prescribe either an echocardiogram or a MUGA (multi-gated acquisition) scan to measure their cardiac function. This will ensure that the chemotherapy dose is well within the range considered safe for the heart. Lung toxicity Damage to the lungs is a serious side effect that can be caused by bleomycin-containing chemotherapy regimens. Patients should report any changes in lung function such as cough, chest pain, or shortness of breath to their doctor, who may decide to monitor their lung health by regularly performing pulmonary function studies during the course of chemotherapy. Other possible side effects Chemotherapy can also cause other side effects such as cough, skin rashes, general weakness, sore throat, and loss of balance or coordination. Patients are sometimes at increased risk for viral infections, particularly shingles (herpes zoster). Many of these side effects are temporary, but some could last for an extended period. Patients should call their doctor if they experience any painful local rash with or without blisters. What side effects are caused by radiation therapy? Radiation therapy itself is painless, but it can cause short-term and long-term side effects. The side effects caused by radiation therapy vary depending on the type of radiation, the radiation dose, and the part of the body treated. Side effects are usually worse when radiation therapy and chemotherapy are given at the same time. 79 Understanding Non-Hodgkin Lymphoma Examples of Potential Short-Term Side Effects of Radiation Therapy n n n n n Radiation to the stomach area can cause nausea, vomiting, and diarrhea. Radiation to the chest and neck can cause a dry sore throat, mouth sores, and trouble swallowing. Radiation to any area may cause hair loss in the area and the skin may become red, dry, and tender. Radiation to the pelvis, legs, and torso (the large areas of your body that contain most of your blood-producing bone marrow) can decrease levels of red blood cells and white blood cells. Examples of Potential Long-Term Side Effects of Radiation Therapy n n n n n n The development of new cancers in the radiated parts of the body. Cardiovascular damage causing an increased risk of heart attack and stroke. Lung damage and problems breathing due to radiation to the chest. Thyroid problems (such as fatigue and weight) later in life due to radiation to the neck. Headaches, memory loss, personality changes, and trouble concentrating due to radiation to the brain. Neck muscle weakness (“neck drop”) causing difficulty lifting the head, and neck pain or discomfort. Dry mouth Some patients treated with radiation therapy experience a temporary decrease in saliva production, or dry mouth (xerostomia). People with dry mouth may have problems swallowing foods or thick liquids. Dry mouth can also cause food particles to stick to the teeth and gums. Because saliva helps prevent cavities, doctors may advise patients to go to the dentist for fluoride treatments before they start radiation therapy. Side Effects and Living With Cancer 80 Part 3 Radiation to any part of the body may cause fatigue, which may progressively worsen during the later weeks of the treatment cycle. Fatigue The likelihood that patients will experience fatigue depends on their disease and the specific radiation plan. Loss of appetite and taste During radiation treatment, patients might lose their appetite for foods that they normally like. The loss of appetite and taste are usually short-term problems. Patients should remember to eat well because their body needs energy and good nutrition to heal. Eating 4 or 5 small meals a day may be more comfortable than eating 2 or 3 larger ones. Patients should ask their healthcare team for information on how to maintain good nutrition during treatment. Nausea Radiation treatment can cause nausea, especially in patients who have radiation to the abdomen. Not eating (especially sweet, spicy, or fatty foods) a few hours before radiation therapy may help avoid nausea. A patient’s doctor may prescribe an anti-nausea (antiemetic) medication to be taken before each radiation therapy session. Skin reactions Radiation therapy can cause skin changes to the affected area such as redness, itchiness, dry and peeling skin, sores or ulcers, swelling, and puffiness. These skin changes usually decrease and disappear over a few weeks after the radiation therapy ends. Some skin changes may last much longer or be permanent. These changes include: darker and blotchy skin, very dry, or thicker skin. The radiated area will sunburn more easily than other parts of your body. Make sure to avoid tanning beds and protect yourself from the sun with a hat, long sleeves, long pants, and sunscreen with an SPF of at least 30. Talk to your doctor or nurse if you notice any skin changes. 81 Understanding Non-Hodgkin Lymphoma Skin Care During and After Radiation Therapy n n n n n n n n n n n n Use lotions and other skin products that your doctor prescribes or your nurse suggests. Do not put anything on your skin that is very hot or cold (such as heating pads or ice packs). Take a shower or bathe in lukewarm water; if you bathe, do it every other day and soak for less than 30 minutes; always use a mild unscented soap; pat dry your skin; do not wash off the ink markings needed for radiation therapy. Check with your doctor or nurse before using bubble bath, cornstarch, cream, deodorant, hair removers, makeup, oil, ointment, perfume, powder, and sunscreen. Part 3 n Be gentle with your skin; do not rub, scrub, or scratch. TIP NT PATIE Wear soft clothes and use soft sheets, such as those made with cotton. Do not wear clothes that are tight and do not allow your skin to breathe. Make your rooms more humid by placing a bowl of water on the radiator or using a properly cleaned and maintained humidifier. Do not sunbathe; protect your skin from the sun every day (use a broad-rimmed hat, long-sleeved shirt, and long pants or skirt outside). Do not use tanning beds. Do not put adhesive tape or bandages on your skin. Ask your nurse about ways to bandage without tape. Ask your doctor or nurse if it is okay to shave the affected area; shave with an electric razor and do not use pre-shave lotion. Report to your doctor or nurse any skin changes you notice. Side Effects and Living With Cancer 82 Throat irritation Radiation therapy to the neck, throat, or chest may cause sore throat, dry mouth, nausea, or cough. Patients may have difficulty eating or swallowing, especially toward the end of their treatment regimen. Patients should tell their doctor if they have problems swallowing. There are treatments for the discomfort. Difficulty swallowing will usually go away after a few weeks of treatment. Easing Throat Irritation During Radiation Therapy n n n n TIP NT PATIE Eat bland foods that are soft, smooth, and easy to digest, such as pudding, yogurt, milk shakes, and commercial dietary supplements. Take small bites and swallow each bite completely before taking another. Try drinking thicker liquids, such as fruit that has been pureed in a blender; they are easier to swallow than thin liquids. Avoid citrus fruits, especially juices. What side effects are caused by steroids? Cortisone, dexamethasone, prednisone, and other corticosteroid drugs can cause side effects such as insomnia (the inability to fall asleep), increased appetite, mood or personality changes, high blood pressure, and weight gain. Prednisone can also trigger diabetes in patients prone to that disease or make diabetes worse in patients who already have the disease. High doses of steroids can also cause osteoporosis in at-risk patients. Patients should tell their family and friends that personality changes may occur during treatment. Patients should avoid making hasty decisions. If personality changes occur, the doctor should be informed—the dose may need to be reduced. 83 Understanding Non-Hodgkin Lymphoma What side effects are caused by rituximab and other antibody (or biologic) therapies? Although side effects caused by biologic therapies vary according to the specific type of treatment, they usually occur during treatment administration and may include flu-like symptoms such as chills, fever, muscle aches, weakness, loss of appetite, nausea, vomiting, and diarrhea. Rituximab (Rituxan) may reduce immunoglobulin levels, especially when given as maintenance therapy. The decrease in immunoglobulin levels can lead to infections (especially sinusitis and upper respiratory infections) which sometimes require treatment with intravenous gammaglobulin. Patients treated with high doses of chemotherapy and/or radiation before undergoing a stem cell transplant are at increased risk for developing infection, bleeding, and other side effects as described perviously (see, “What side effects are caused by chemotherapy?” and “What side effects are caused by radiation therapy?”). Patients receiving high-dose chemotherapy with autologous stem cell support (autologous stem cell transplantation) are followed carefully for the first 3-4 weeks because of the risks of mouth sores (mucositis), infection, anemia (low red blood cell count causing fatigue), and bleeding. Transfusions and antibiotics, often in the hospital, may be necessary. Patients receiving stem cells from a sibling or unrelated donor are also at risk of developing graft-versus-host disease (GVHD), a condition where the donated marrow’s immune system attacks the patient’s tissues. GVHD can happen at any time after the transplant. Drugs can be used to reduce the risk of developing GVHD or to treat the problem once it develops. Side Effects and Living With Cancer 84 Part 3 What side effects are caused by stem cell transplantation? More information about stem cell transplantation and its effects can be found at www.bethematch.org. When should a patient’s doctor be called? As a general rule: n n n 85 Call if the patient experiences a side effect that is unexpected or lasts longer than expected. Call if the patient experiences a medical problem—such as high fever, shortness of breath, prolonged or constant nausea and vomiting, chest pains, and dizziness—that cannot wait for a regularly scheduled appointment. If the patient’s doctor or nurse cannot be reached, go to the hospital emergency room for a medical assessment and place another call to the doctor. Understanding Non-Hodgkin Lymphoma Part 3 — Side Effects and Living With Cancer Chapter 8: Managing Your Life During and After Treatment This chapter talks about some general issues that patients may encounter while they live their life during and after treatment. Coping strategies Each person’s experience with cancer is different, and how he or she copes with the physical and emotional impact of having NHL is unique to a patient’s personality and situation. Here are some suggestions for how to cope with some issues that patients may face. ■ ■ ■ ■ Get Help for Depression ■ ■ ■ ■ Deal with Physical Changes ■ ■ ■ ■ Maintain a Healthy Lifestyle Set Reasonable Goals ■ ■ ■ ■ ■ ■ Communicate your fears and concerns about your disease by talking with your family, friends, doctors, and counselors. Writing down your concerns in a journal may also help. Find a support group or other individuals who are also coping with cancer. Feeling sad or depressed is not unusual in people living with cancer. Watch out for signs of depression: sleeping more or less than usual; feeling a lack of energy; crying; inability to concentrate. Ask for a referral to a psychiatrist, social worker, psychologist, or counselor who will help you cope with your feelings through talk therapy, medications, or both. Find a support group of people who have had similar experiences. Some patients with cancer feel unattractive because of hair loss and other changes in appearance caused by their treatment. Ask your doctor what changes you should expect; plan ahead and buy a wig or head covering if hair loss is a possibility. Get advice from a beautician about makeup for the areas that you consider a problem. Ask your healthcare team for advice on how to manage temporary changes such as dry skin, brittle nails, and a blotchy complexion. Eat a healthy diet that includes fruits, vegetables, protein, and whole grain. Engage in regular physical exercise; this can reduce anxiety, depression, and fatigue, and improve mood. Get sufficient rest to help combat the stress and fatigue of your disease and its treatment. Quit smoking and reduce alcohol consumption. Having goals for how you want to live your life during and after treatment will help you maintain a sense of purpose. Avoid setting unreasonable goals, such as deciding to work full-time while part-time would be much better for your health. Stay as active and involved as you can in work and other activities that interest you. Side Effects and Living With Cancer 86 Part 3 Maintain a Strong Support System The importance of pain control Patients may feel pain from the cancer itself or from treatments and procedures. Cancer pain is very treatable and there is no reason for a patient to tough it out without help. Patients should tell their doctors and nurses if they have any pain because doctors and nurses can offer advice regarding medications and other ways to relieve the pain. Different types of pain are best controlled by different types of pain relievers: n n n n n n 87 Mild to moderate pain can be treated with acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen. Moderate to severe pain is best controlled with opioids such as morphine, hydromorphone, oxycodone, and hydrocodone. Tingling and burning pain can be controlled with anti-depressants and anti-epileptics. Pain caused by swelling can be controlled by steroids such as prednisone and dexamethasone. Non-drug pain treatments include: biofeedback, breathing and relaxation exercises, distraction, heat or cold packs (avoid these following radiation therapy), hypnosis, imagery, massage, pressure and vibration, and transcutaneous electrical nerve stimulation (TENS). If the pain is not relieved by medicines and non-drug pain management, the following treatments can also be used to relieve the source of the pain: radiation therapy, nerve blocks/implanted pump, neurosurgery, and surgery. Understanding Non-Hodgkin Lymphoma Managing Pain n Tell your doctor or nurse about your pain. Be specific when you describe it. TIP NT PATIE – Where do you feel the pain? – What type of pain is it (sharp, dull, throbbing)? – Does it come and go, or is it steady? – How strong is it? How long does it last? – Does anything make the pain feel better or worse? – Which drugs have you taken for the pain? Do they help? If so, for how long? n n n n Take your pain medication on a regular schedule even if the pain seems to be better. Do not skip doses. Part 3 n Tell your family and friends about your pain so that they can help you and so that they can understand why you may be acting differently. Try deep breathing, yoga, or other ways to relax. Ask to meet with a pain specialist or palliative care specialist to help you find better ways to control your pain. Tell your doctor or nurse of any changes in your pain. Maintain a healthy lifestyle Regular physical activity helps keep the cardiovascular system strong and body muscles flexible. Exercise can also help alleviate breathing problems, constipation, and mild depression. It also helps reduce stress and fatigue. Patients should talk to their doctor before starting an exercise program. Side Effects and Living With Cancer 88 Several types of exercise are particularly helpful: n n n n General physical activity, such as swimming, dancing, household chores, and yard work. Aerobic activity to improve cardiovascular fitness, such as walking, jogging, and bicycling. Resistance training to strengthen muscles, protect joints, and help remedy osteoporosis by building bone mass. Flexibility exercises such as stretching and yoga to improve range of motion, balance, and stability. Eating a healthy diet is especially important during treatment for NHL because it will help patients keep up their strength and energy, tolerate treatment-related side effects, decrease their risk of infection, and heal and recover more quickly. Patients should aim for a diet high in fruits and vegetables, protein (poultry, fish, and eggs), and whole grains. During chemotherapy and after a stem cell transplant, a patient may temporarily be asked to avoid raw fruits and vegetables that may increase the risk of infection if you have a low white blood cell count (“neutropenic diet”). A patient’s healthcare team can help put together an eating plan that is appropriate. Patients should talk to their doctor before taking any dietary supplements such as multivitamins or individual vitamin supplements, as well as any herbal or “natural” supplements, because they may interfere with treatments or have unexpected side effects. The importance of follow-up care At the first visit following the completion of treatment, patients should talk to their doctor about their follow-up schedule. This will be different from patient to patient depending on their disease type, age, and general health. Patients should adhere to their schedule of follow-up visits—these are very important for monitoring disease recurrence and detecting and treating any health problems that might have been caused by the treatment. 89 Understanding Non-Hodgkin Lymphoma During these follow-up visits, the doctor will ask about any medical changes since the last appointment and give a physical examination; the doctor may also prescribe imaging, blood, molecular diagnostic, or other laboratory tests. Be proactive in healthcare decisions To stay proactive in healthcare decisions, patients should get the following information from their medical team: n n Copies of their medical records and a written summary of their treatment in case they switch oncologists or need to see a primary care physician for routine medical care. A list of signs of disease recurrence and late side effects from treatment. n Any new symptoms. n Pain. n n Physical problems that disrupt their daily life such as fatigue, insomnia, sexual dysfunction, and weight gain or loss. Any new health problems, such as heart disease, diabetes, and high blood pressure. n Any new medications and vitamins they are taking. n Emotional problems such as anxiety and depression. n Any other questions or concerns. Side Effects and Living With Cancer 90 Part 3 At the follow-up care appointments, patients should be sure to tell their doctor about: Part 4 — Clinical Trials and Advances in Treatment Chapter 9: Overview of Clinical Trials There are hundreds of NHL clinical trials now underway in hospitals, cancer centers, and doctors’ offices around the country. The government, pharmaceutical and biotechnology companies, universities, and doctor groups often sponsor clinical trials. The United States Food and Drug Administration (FDA) and the institutional review board (IRB) of participating hospitals or institutions must approve all clinical trials. What is a clinical trial? A clinical trial is a carefully designed research study that involves people who volunteer to participate. Clinical trials are also sometimes referred to as clinical studies. However, the term “clinical study” is broadly used to describe many different sorts of studies in addition to those described in this chapter. The purpose of clinical trials in cancer is to answer questions about new ways to treat, diagnose, prevent, or manage a disease or the side effects caused by treatments. Strict rules and oversight procedures make sure that clinical trials are designed and run in a way that protects the rights and safety of the people who volunteer to participate. In the United States, a new drug must pass through a strict approval process governed by the FDA before it can become a standard therapy for use in people. The FDA-regulated approval process for drugs includes preclinical studies (done in laboratories) and clinical trials (done in hospitals and clinics). As shown in the following table, there are 4 main types (or phases) of clinical trials. The first 3 are usually required before a drug is considered for approval by the FDA. Phase IV studies are performed after a drug has received FDA approval; these trials are sometimes called post-marketing studies. Patients may be eligible to take part in different types of clinical trials depending on their health status, type 91 Understanding Non-Hodgkin Lymphoma and stage of lymphoma, and type of treatment, if any, they previously received. Phase Description Phase I n To find a safe dose. n To decide on a treatment regimen. n Phase II n n Phase III n n n n 15-30 people with one or more different types of cancer. To see if the treatment causes any side effects. To find out if a new treatment has an effect against a certain type of cancer. n Usually fewer than 100 people with the same type of cancer. To see if the treatment causes any side effects. To compare new treatments or new uses of existing treatments with current standard treatments. The main things being compared usually are how well the treatment works and what type of side effects it causes. To get more information about the long-term safety and effectiveness of a new treatment. n n n From 100 to several thousand people with the same type of cancer. Patients are randomly assigned to a treatment group; one group receives the standard therapy and the other group receives the experimental treatment. Several hundred to several thousand people with the same type of cancer. Why is a placebo sometimes used in phase III trials? A placebo is an inactive ingredient that is used as a comparator in some clinical trials. In such trials neither the patients nor the doctors and nurses treating them will know which patients receive a placebo versus the experimental drug. In cancer clinical trials, patients are never given a placebo in place of an effective standard therapy. They would be given a placebo only if there were no standard therapies to compare against. Placebo-controlled trials are never done in a manner to deny patients an effective therapy. Clinical Trials and Advances in Treatment 92 Part 4 Phase IV Number of Volunteer Patients Should I participate in a clinical trial? Clinical trials are not a last resort for patients. Patients with all stages of NHL can often benefit from participation in clinical trials, whether at the time of initial diagnosis or at relapse. Clinical trials offer patients therapies that are not otherwise available to all patients. Another advantage of clinical trials is that the health of enrolled patients is monitored very carefully. In many cases, patients can benefit more from participation in clinical trials than from receiving standard therapies. Some professional organizations, like the National Comprehensive Cancer Network (www.nccn.com), actively encourage the participation of patients with cancer in clinical trials because they provide the best management for any cancer patient. What is informed consent? Informed consent is a process through which people learn all about the clinical trials they are interested in joining. During this process, members of the clinical trial research team will explain: n n n The purpose of the study. The factors used to decide if a patient is allowed to participate in the study. The tests, procedures, and visits participants will be expected to agree to. n The type of treatment provided in the study. n The possible risks and benefits. n 93 The rights of patients to decide whether or not to participate, and to leave the study at any time. Understanding Non-Hodgkin Lymphoma The research team will answer your questions and provide written information about the trial. If patients agree to participate in a clinical trial, they will be asked to read and sign an informed consent form that details all the trial information discussed and describes how their records will be kept private. Remember that even after signing the consent form, patients can leave the study at any time. Questions to Ask About a Clinical Trial n What is the purpose of this clinical trial? n Why are you recommending this clinical trial for me? n Who is sponsoring this trial (the National Cancer Institute, a cancer center, a pharmaceutical/biotechnology company)? Who has reviewed and approved this clinical trial? n Does this clinical trial include the use of a placebo (sugar pill)? n How long will the study last? Where will it take place? n What are the risks involved? n What are the possible benefits? n What are my responsibilities during the clinical trial? Part 4 n n TIP NT PATIE What kinds of tests, procedures, or treatments will be performed? How many and how often? n Will I be in any discomfort or pain? n Will I be able to see my own doctor during the clinical trial? n What costs will I be responsible for? n What happens if my health gets worse during the clinical trial? Clinical Trials and Advances in Treatment 94 What is the cost of participating in a clinical trial? Clinical trials are very expensive undertakings for the study sponsor. Patient costs vary depending on the study, who is sponsoring the trial, what portion of the trial-related expenses the sponsor will cover, and the patient’s health insurance coverage. Some health insurance and managed healthcare providers will pay for the basic medical procedures associated with the trial, such as lab tests, scans, and hospitalization when required, while others may define clinical trials as “experimental” or “investigational” and not cover some of the routine costs, such as doctor visits, tests, or treatments. Medicare provides coverage for patient care associated with government-sponsored clinical trials. If a patient is taking part in a National Cancer Institute (NCI) trial being conducted at the National Institutes of Health (NIH) in Bethesda, Maryland, the NCI will pay for the study drug and the costs related to the study. A stipend for travel, food, and lodging is also provided. Some cancer centers provide financial assistance or discounted rates for room and board and have special research units that will pay for study-related costs. Some organizations, including the Lymphoma Research Foundation, provide financial assistance for treatmentrelated expenses. Patients should ask their doctor what clinical trials may be most appropriate for them. Here are some additional sources of clinical trial information: n n n n 95 The Lymphoma Helpline at the Lymphoma Research Foundation at (800) 500-9976. Cancer centers in your area. The Coalition of Cancer Cooperative Groups website at www.cancertrialshelp.org. The NIH websites www.cancer.gov and www.clinicaltrials.gov. Understanding Non-Hodgkin Lymphoma Part 4 — Clinical Trials and Advances in Treatment Chapter 10: Advances in Treatment of Patients With Non-Hodgkin Lymphoma Doctors and scientists around the world are working very hard to improve currently available treatment options and find better and safer drugs to treat patients with NHL. Advances are being made in different areas including: genetics, treatments, and supportive care. Drugs that are not yet approved for sale by the FDA are said to be investigational. Some of these investigational drugs are being studied in laboratory experiments using tissue culture cells and laboratory animals. The drugs that are in more advanced stages of research are being studied in patients in clinical trials. Remember that today’s science is moving very fast. Please check with the Lymphoma Research Foundation or the doctor for additional information and recent updates. For a detailed discussion of currently approved treatment options, please see Chapter 6, “Treatments for Non-Hodgkin Lymphoma.” Chemotherapy Researchers are trying to develop new chemotherapy drugs, make improved versions of existing drugs, and find better ways to combine different doses and sequences of existing drugs. The goal is to make drugs that are better at killing lymphoma cells while leaving healthy cells alone (decreasing the chance of side effects). Clinical Trials and Advances in Treatment 96 Part 4 The most common way for a patient to receive an investigational drug is through a clinical trial. To find out more about getting access to investigational drugs go to the website for the National Cancer Institute at www.cancer.gov and search for “access to investigational drugs.” Stem cell transplantation Ongoing research in stem cell transplantation is focused on: finding better ways to collect stem cells from the bone marrow or peripheral blood; eliminating graft-versus-host disease in allogeneic (donor) transplants; improving ways to remove all lymphoma cells from stem cell samples used for autologous (self) transplants; and developing more effective non-myeloablative (reduced-intensity) stem cell transplants. Monoclonal antibodies Monoclonal antibodies are molecules made in the laboratory that are designed to recognize and stick to specific molecules on cancer cells. When a monoclonal antibody attaches itself to a cancer cell, it can stop or slow down its growth or it can make it easier for the immune system to recognize it and kill it. The success of the monoclonal antibody rituximab (Rituxan) inspired researchers to develop other monoclonal antibodies to treat patients with NHL. Many monoclonal antibodies are being investigated in clinical trials, including obinutuzumab (GA101), ocrelizumab, epratuzumab, lucatumumab (HCD122), blinatumomab (AMG 103), AME-133v, and others. Other targeted therapies In addition to monoclonal antibodies that target molecules on cell surfaces, many drugs are in development that target molecules inside cancer cells. A better understanding of the biology and genetics of NHL is helping researchers identify specific molecules in lymphoma cells that may be good targets for new drugs. These specific molecules usually have important roles in controlling the growth and survival of lymphoma cells. The drugs that target these molecules are broadly called targeted therapies. These drugs may kill the lymphoma cells or slow down or stop their growth. Targeted therapies attack cancer cells in a more specific way than chemotherapy drugs. Many targeted therapies for NHL are being studied in laboratories and in clinical trials. Examples include: immunomodulating agents (IMiDs) such as lenalidomide (Revlimid), which target molecules involved 97 Understanding Non-Hodgkin Lymphoma in immune function; histone deacetylase (HDAC) inhibitors such as romidepsin (Istodax) and vorinostat (Zolinza), which target molecules that help control which proteins are produced by a cell; mammalian target of rapamycin (mTOR) inhibitors such as temsirolimus (Torisel) and everolimus (Afinitor), which target molecules in cell biochemistry pathways involved in cell growth and division; inhibitors of Bcl2 such as ABT-263 (navitoclax), which target molecules that prevent cell death; aurora kinase inhibitors such as MLN8237 (alisertib), which interfere with normal cell division; purine nucleoside phosphorylase (PNP) inhibitors such as forodesine, which results in T- and B-cellspecific apoptosis (cell death); and inhibitors of B-cell receptor molecules such as ibrutinib (PCI-32765) and GS-1101, which also trigger cell death. Proteasome inhibitors Several novel proteasome inhibitors are also currently being tested in clinical trials of various NHL types, including carfilzomib, NPI-0052, CEP-18770, MLN9708, and others. Vaccines Researchers are trying to develop vaccines to help treat, not prevent, lymphomas. The hope is that these vaccines would boost a person’s own immune system so that it would recognize and kill lymphoma cells early during the course of the disease. This type of vaccine therapy is also being studied in other types of cancer such as prostate cancer and melanoma. There are no currently approved cancer vaccines for NHL, but several are actively being tested in clinical trials. Clinical Trials and Advances in Treatment 98 Part 4 Bortezomib (Velcade) is a proteasome inhibitor currently approved for multiple myeloma and mantle cell lymphoma. Bortezomib is currently being investigated, either alone or in combination with other drugs, for other NHL types, including follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, several T/NK-cell lymphomas, and Waldenström macroglobulinemia. ABOUT THE LYMPHOMA RESEARCH FOUNDATION The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization devoted to funding innovative research and providing people with lymphoma and healthcare professionals with up-to-date information about this type of cancer. LRF’s mission is to eradicate lymphoma and serve those touched by this disease. The Foundation remains dedicated to finding a cure for lymphoma through an aggressively-funded research program and by supporting the development of improved therapies for people living with lymphoma. LRF provides a comprehensive series of programs and services for people with lymphoma, their loved ones, and caregivers. How the Lymphoma Research Foundation Serves the Lymphoma Community Research LRF remains dedicated to finding a cure for lymphoma through an aggressively-funded research program. LRF supports innovative research through Clinical Investigator Career Development Awards, Fellowships, and several disease-specific research initiatives. These focused initiatives include: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Initiative; Diffuse Large B-Cell Lymphoma Initiative; Follicular Lymphoma Initiative; and Mantle Cell Lymphoma Initiative and Consortium. The Foundation’s volunteer Scientific Advisory Board (SAB), comprised of 45 world-renowned lymphoma experts, guides the Foundation’s research activities, seeking out the most innovative and promising lymphoma research projects for support. 99 Understanding Non-Hodgkin Lymphoma Programs and Services LRF provides a comprehensive series of programs and services for the lymphoma community, including: n Clinical Trials Information Service n Disease-Specific Publications and Websites n In-person Workshops and Educational Forums n Lymphoma Helpline n Lymphoma Support Network n Online Resources, Teleconferences, and Webcasts/Podcasts n Patient Aid Grants Professional Education LRF is committed to educating healthcare professionals on the latest developments in lymphoma diagnosis and treatment. The Foundation offers a wide range of lymphoma-focused continuing education activities for nurses, physicians, and social workers, including workshops, conference symposia, and webcasts. Public Policy and Advocacy LRF represents the needs of people with lymphoma by supporting public policies which seek to increase federal funding for lymphoma research and ensure access to high quality cancer care. The LRF Advocacy Program provides volunteer advocates with the resources necessary to garner attention and support for those public policies most important to the lymphoma community. There are currently more than 5,000 LRF advocates in all 50 states and the District of Columbia. About the Lymphoma Research Foundation 100 Chapter Network Through its nationwide chapter network, LRF meets the needs of the lymphoma community on the local level. Chapter volunteers reach out to newly diagnosed patients; raise funds for research; and participate in advocacy efforts. There are 18 chapters in 16 states. Contact Information LRF National Headquarters 115 Broadway, Suite 1301 New York, NY 10006 (212) 349-2910 Fax (212) 349-2886 [email protected] www.lymphoma.org LRF Helpline (800) 500-9976 [email protected] 101 Understanding Non-Hodgkin Lymphoma